WO2011068403A2 - Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts - Google Patents
Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts Download PDFInfo
- Publication number
- WO2011068403A2 WO2011068403A2 PCT/NL2010/050809 NL2010050809W WO2011068403A2 WO 2011068403 A2 WO2011068403 A2 WO 2011068403A2 NL 2010050809 W NL2010050809 W NL 2010050809W WO 2011068403 A2 WO2011068403 A2 WO 2011068403A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salt
- cancer
- eriotinib
- group
- erlotinib
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims description 67
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims abstract description 41
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims abstract description 37
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 37
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims abstract description 31
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims abstract description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 201000011510 cancer Diseases 0.000 claims abstract description 21
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims abstract description 16
- 229940116871 l-lactate Drugs 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 13
- 230000003463 hyperproliferative effect Effects 0.000 claims abstract description 12
- 150000003890 succinate salts Chemical class 0.000 claims abstract description 9
- 150000004923 Erlotinib derivatives Chemical class 0.000 claims abstract description 4
- 239000012458 free base Substances 0.000 claims description 101
- 239000007787 solid Chemical group 0.000 claims description 84
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 39
- 241001658031 Eris Species 0.000 claims description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 33
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 24
- 241000124008 Mammalia Species 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- 208000035475 disorder Diseases 0.000 claims description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 14
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 claims description 14
- -1 1,4-dioxane L-lactate Lactic acid methylacetate Chemical compound 0.000 claims description 12
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 11
- 229940093499 ethyl acetate Drugs 0.000 claims description 11
- 235000019439 ethyl acetate Nutrition 0.000 claims description 11
- 201000004681 Psoriasis Diseases 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 210000002307 prostate Anatomy 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 8
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 8
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 7
- 210000000481 breast Anatomy 0.000 claims description 7
- 210000004072 lung Anatomy 0.000 claims description 7
- 230000002611 ovarian Effects 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 6
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000017169 kidney disease Diseases 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 150000003895 L-lactate salts Chemical class 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 206010020718 hyperplasia Diseases 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 206010000830 Acute leukaemia Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 206010006143 Brain stem glioma Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 3
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 206010061252 Intraocular melanoma Diseases 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 3
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 208000017442 Retinal disease Diseases 0.000 claims description 3
- 206010038923 Retinopathy Diseases 0.000 claims description 3
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 201000005969 Uveal melanoma Diseases 0.000 claims description 3
- 201000003761 Vaginal carcinoma Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 210000004100 adrenal gland Anatomy 0.000 claims description 3
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
- 230000033115 angiogenesis Effects 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 210000001109 blastomere Anatomy 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 208000037976 chronic inflammation Diseases 0.000 claims description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 3
- 208000024207 chronic leukemia Diseases 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 3
- 210000000750 endocrine system Anatomy 0.000 claims description 3
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 201000001343 fallopian tube carcinoma Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000011066 hemangioma Diseases 0.000 claims description 3
- 238000002513 implantation Methods 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 230000001926 lymphatic effect Effects 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002575 ocular melanoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 230000000849 parathyroid Effects 0.000 claims description 3
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 3
- 201000008171 proliferative glomerulonephritis Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 201000003708 skin melanoma Diseases 0.000 claims description 3
- 210000000813 small intestine Anatomy 0.000 claims description 3
- 210000004872 soft tissue Anatomy 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 230000005747 tumor angiogenesis Effects 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 210000003708 urethra Anatomy 0.000 claims description 3
- 208000037965 uterine sarcoma Diseases 0.000 claims description 3
- 230000004862 vasculogenesis Effects 0.000 claims description 3
- 208000013013 vulvar carcinoma Diseases 0.000 claims description 3
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 claims description 2
- 150000003842 bromide salts Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002690 malonic acid derivatives Chemical class 0.000 claims description 2
- 101100427549 Arabidopsis thaliana ULT2 gene Proteins 0.000 claims 5
- 206010046458 Urethral neoplasms Diseases 0.000 claims 4
- 208000019065 cervical carcinoma Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- NEQCSNXWDAPVAB-UHFFFAOYSA-N COC(C)=O.C(CC(=O)O)(=O)O.C(CC(=O)O)(=O)O Chemical compound COC(C)=O.C(CC(=O)O)(=O)O.C(CC(=O)O)(=O)O NEQCSNXWDAPVAB-UHFFFAOYSA-N 0.000 claims 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims 1
- FCYLXYCLDHBRMR-UHFFFAOYSA-N FC(CO)(F)F.C(CCC(=O)O)(=O)O.C(CCC(=O)O)(=O)O.C(C)OC(C)=O Chemical compound FC(CO)(F)F.C(CCC(=O)O)(=O)O.C(CCC(=O)O)(=O)O.C(C)OC(C)=O FCYLXYCLDHBRMR-UHFFFAOYSA-N 0.000 claims 1
- SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 238000010792 warming Methods 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 abstract description 138
- 239000005551 L01XE03 - Erlotinib Substances 0.000 abstract description 114
- 229960001433 erlotinib Drugs 0.000 abstract description 114
- JLKNFSVHIZLRAA-UHFFFAOYSA-N 1-[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]-2-(3-ethynylphenyl)hydrazine Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NNC1=CC=CC(C#C)=C1 JLKNFSVHIZLRAA-UHFFFAOYSA-N 0.000 abstract description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 62
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 38
- 238000006243 chemical reaction Methods 0.000 description 29
- 239000011521 glass Substances 0.000 description 29
- 239000011343 solid material Substances 0.000 description 28
- 239000012452 mother liquor Substances 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 21
- 238000004128 high performance liquid chromatography Methods 0.000 description 18
- 238000003756 stirring Methods 0.000 description 17
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 15
- 238000001757 thermogravimetry curve Methods 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 12
- 238000001069 Raman spectroscopy Methods 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 238000011179 visual inspection Methods 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 8
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 8
- 238000011088 calibration curve Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 238000010907 mechanical stirring Methods 0.000 description 7
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000009246 food effect Effects 0.000 description 6
- 235000021471 food effect Nutrition 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 239000001384 succinic acid Substances 0.000 description 6
- QKRMFCXDTFLKKT-UHFFFAOYSA-N 2-hydroxyethanesulfonic acid Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O QKRMFCXDTFLKKT-UHFFFAOYSA-N 0.000 description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
- 239000010414 supernatant solution Substances 0.000 description 5
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- 229940100197 antimetabolite Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- PCBNMUVSOAYYIH-UHFFFAOYSA-N n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine;methanesulfonic acid Chemical class CS(O)(=O)=O.C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 PCBNMUVSOAYYIH-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101100478266 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SPT10 gene Proteins 0.000 description 2
- 101100352819 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pop2 gene Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 230000003388 anti-hormonal effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229910052738 indium Inorganic materials 0.000 description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 101150095121 sud1 gene Proteins 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 238000001237 Raman spectrum Methods 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 239000010431 corundum Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960005073 erlotinib hydrochloride Drugs 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000028149 female reproductive system neoplasm Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 239000012444 intercalating antibiotic Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- AQRYNYUOKMNDDV-UHFFFAOYSA-M silver behenate Chemical compound [Ag+].CCCCCCCCCCCCCCCCCCCCCC([O-])=O AQRYNYUOKMNDDV-UHFFFAOYSA-M 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to novel salts and polymorphs thereof of N-(3- ethynylphenylamino)-6,7-bis ⁇ 2-methoxyethoxy)-4-quinazolinamine (Erlotinib).
- the invention also relates to pharmaceutical compositions containing Erlotinib salts and to the methods of treating hyperproliferative disorders such as cancer, by administering Erlotinib salts.
- the present invention relates to novel salts of Erlotinib and polymorphs of theses salts.
- This quinazolamine compounds are useful in the treatment of hyperproliferative disorders such as cancers in mammals.
- United States patent number 5,747,498 filed May 28, 1996 refers to Erlotinib hydrochloride which, the patent application discloses, is an inhibitor of the erbB family of oncogenic and protooncogenic protein tyrosine kinases, such as the epidermal growth factor receptor (EGFR), and is therefore useful for the treatment of proliferative disorders such as cancers in humans.
- United States patent number 6,706,721, filed April 08, 1999 refers to Erlotinib mesylate salt.
- US patent publication 2002/006,443 discloses the solubility of the mesylate salt of Erlotinib being in the range of approximately 30 pg/mL to 100 pg/mL.
- hydrochloric and mesylate compound have very limited solubility in aqueous compositions which limits their bioavailability and gives rise to an undesirable strong food effect. Limited solubility also limits the dosing route and formulation to a solid oral dosage form.
- mesylates have an inherent problem in the way that a toxic impurity in the form of ethyl methanesulfonate can be formed in certain circumstances.
- novel salts are all more soluble in aqueous compositions than the above mentioned hydrochloride compound, and thus the novel salts of the present invention will posses increased bioavailability, a reduction of the food effect and can be formulated for possible dosing routes. Furthermore, the toxic effect of ethyl methanesulfonate can be avoided.
- the present inventors have found different salts and/or solid forms of Eriotinib which are useful for the treatment of proliferative disorders. It has been found that these salts and solid forms possess certain advantages over the prior art hydrochloride and mesylate compounds. It has been found that providing the novel salts in crystalline from provides for an enhanced stability until administration as a liquid and may be easier I the purification step at the end of the synthesis process. It has been found that the salts of the present invention are more soluble in aqueous compositions than the above mentioned hydrochloride, and thus the novel salts of the present invention will posses increased bioavailability, a reduction of the food effect and can be formulated for possible dosing routes.
- the invention relates to Eriotinib ethanesulfonate, isethionate, bromide, malonate, L-iactate and succinate in anhydrous and hydrated forms and polymorphic forms thereof.
- the present invention relates to anhydrous and hydrated salts of Eriotinib.
- Another embodiment of the present invention relates to the isethionate salt of Eriotinib.
- Another embodiment of the present invention relates to the bromide salt of Eriotinib.
- Another embodiment of the present invention comprises the malonate salt of Eriotinib.
- Another embodiment of the present invention comprises the L-lactate salt of Eriotinib.
- Another embodiment of the present invention comprises the succinate salt of Erlotinib.
- the invention further relates to a pharmaceutical composition for the treatment of hyperproliferative disorder, specifically non-small cell lung cancer and bronchioalveolar cancer, in a mammal, including a human, which comprises a therapeutically effective amount of Erlotinib ethanesulfonate, isethionate, bromide, malonate, L-lactate and succinate and a pharmaceutical acceptable carrier.
- said pharmaceutical composition is for the treatment of cancers.
- the invention also relates to a pharmaceutical composition for the treatment of pancreatitis or kidney disease (including proliferative glomerulonephritis and diabetes- induced renal disease) in a mammal, including a human, which comprises a therapeutically effective amount of Erlotinib ethanesulfonate, isethionate, bromide, malonate, L-lactate and succinate and a pharmaceutical acceptable carrier.
- the invention also relates to a pharmaceutical composition for the prevention of blastocyte implantation in a mammal, including a human, which comprises a therapeutically effective amount of Erlotinib ethanesulfonate, isethionate, bromide, malonate, L-lactate and succinate salt and a pharmaceutical acceptable carrier.
- the invention also relates to a pharmaceutical composition for treating a disease related to vasculogenesis or angiogenesis in a mammal, including a human, which comprises a therapeutically effective amount of Erlotinib ethanesulfonate, isethionate, bromide, malonate, L-lactate and succinate salt and a pharmaceutical acceptable earner.
- said pharmaceutical composition is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, skin diseases such as psoriasis, eczema, and scleroderma, diabetes, diabetes retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
- a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, skin diseases such as psoriasis, eczema, and scleroderma
- diabetes diabetes retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma,
- the invention also relates to a method of treating hyperproliferative disorder in a mammal, including a human, which comprises administering to said mammal a therapeutically effective amount of Erlotinib ethanesulfonate, isethionate, bromide, malonate, L-factate and succinate salt.
- said method relates to the treatment of cancer such as brain, lung, squamous cell, bladder, gastric, pancreatic, breast, neck, head, renal (such as kidney), ovarian, prostate, colorectal, oesophageal, gynecological or thyroid cancer.
- said pharmaceutical composition is for the treatment of non-cancerous hyperproliferative disorder such being benign hyperplasia of the skin (e.g. psoriasis) or prostate (e.g. benign prostatic hypertrophy (BPH)).
- non-cancerous hyperproliferative disorder such being benign hyperplasia of the skin (e.g. psoriasis) or prostate (e.g. benign prostatic hypertrophy (BPH)).
- the invention also relates to a method of treatment of a hyperproliferative disorder in a mammal, including a human, which comprises administering to said mammal a therapeutically effective amount of Erlotinib ethanesulfonate, isethionate, bromide, malonate, L-lactate and succinate salt, optionally in combination with an anti- tumor agent selected from the group of mitotic inhibitors, alkylating agents, antimetabolites, intercalating agents, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, and anti- androgens.
- an anti- tumor agent selected from the group of mitotic inhibitors, alkylating agents, antimetabolites, intercalating agents, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, and anti- androgens.
- Patients that can be treated with Erlotinib ethanesulfonate, isethionate, bromide, malonate, L-lactate and succinate salt according to the methods of this invention include, for example, patients that have been diagnosed as having psoriasis, BPH, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, ovarian cancer, rectal cancer, cancer of he anal region, stomach cancer, colon cancer, breast cancer, gynecologic tumors (e.g., uterine sarcomas, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of he cervix, carcinoma of the vagina or carcinoma of the vulva), Hodgkin's disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system (e.g., cancer of the thyroid, parathyroid or adrenal glands), sarcomas
- Figure 1A illustrates the high resolution X-Ray Powder Diffraction pattern of Erlotinib ethanesulfonate ERET ULT-1
- Figure 1B illustrates the DSC thermogram of Erlotinib ethanesulfonate ERET ULT-1
- Figure 1C illustrates the TGA thermogram of Erlotinib ethanesulfonate ERET ULT-1
- Figure 2A illustrates the high, resolution X-Ray Powder Diffraction pattern of Erlotinib ethanesulfonate ERET ULT-2
- Figure 2B illustrates the DSC thermogram of Erlotinib ethanesulfonate ERET ULT-2
- Figure 2C illustrates the TGA thermogram of Erlotinib ethanesulfonate ERET ULT-2
- Figure 2D illustrates the Raman spectrogram of Erlotinib ethanesulfonate ERET ULT-2
- Figure 2E illustrates the FT-IR spectrogram of Erlotinib ethanesulfonate ERET ULT-2
- Figure 3A illustrates the high resolution X-Ray Powder Diffraction pattern of Erlotinib isethionate ERIS ULT-1
- Figure 3B illustrates the DSC thermogram of Erlotinib isethionate ERIS ULT-1
- FIG. 3C illustrates the TGA thermogram of Erlotinib isethionate ERIS ULT-1
- FIG. 3D illustrates the TGA thermogram (top) and MS spectrum (bottom) of Erlotinib isethionate ERIS ULT-1
- Figure 3E illustrates the Raman spectrogram of Erlotinib isethionate ERIS ULT-1
- Figure 3F illustrates the FT-IR spectrogram of Erlotinib isethionate ERIS ULT-1
- Figure 4A illustrates the X-Ray Powder Diffraction pattern of Erlotinib isethionate ERIS ULT-2
- FIG. 4B illustrates the TGA thermogram of Erlotinib isethionate ERIS ULT-2
- FIG. 4C illustrates the TGA thermogram (top) and MS spectrum (bottom) of Erlotinib isethionate ERIS ULT-2
- Figure 5A illustrates the X-Ray Powder Diffraction pattern of Erlotinib isethionate ERIS ULT-3
- Figure 5B illustrates the TGA thermogram of Eriotinib isethionate ERIS ULT-3
- FIG. 5C illustrates the TGA thermogram (top) and MS spectrum (bottom) of Eriotinib isethionate ERIS ULT-3
- Figure 6 illustrates the X-Ray Powder Diffraction pattern of Eriotinib isethionate ERIS ULT-4
- Figure 7A illustrates the high resolution X-Ray Powder Diffraction pattern of Eriotinib bromide ERBR ULT-1
- Figure 7B illustrates the DSC thermogram of Eriotinib bromide ERBR ULT-1
- Figure 7C illustrates the TGA thermogram of Eriotinib bromide ERBR ULT-1
- Figure 7D illustrates the Raman spectrogram of Eriotinib bromide ERBR ULT-1
- Figure 7E illustrates the FT-IR spectrogram of Eriotinib bromide ERBR ULT-1
- Figure 8 illustrates the X-Ray Powder Diffraction pattern of Eriotinib bromide ERBR ULT-2
- Figure 9A illustrates the X-Ray Powder Diffraction pattern of Eriotinib bromide ERBR ULT-3
- Figure 9B illustrates the TGA thermogram of Eriotinib bromide ERBR ULT-3
- Figure 10 illustrates the X-Ray Powder Diffraction pattern of Eriotinib bromide ERBR ULT-4
- Figure 11 illustrates the X-Ray Powder Diffraction pattern of Eriotinib bromide ERBR ULT-5
- Figure 12A illustrates the high resolution X-Ray Powder Diffraction pattern of Eriotinib malonate ERMO ULT-1
- Figure 12B illustrates the DSC thermogram of Eriotinib malonate ERMO ULT-1
- Figure 12C illustrates the TGA thermogram of Eriotinib malonate ERMO ULT-1
- Figure 12D illustrates the Raman spectrogram of Eriotinib malonate ERMO ULT-1
- Figure 12E illustrates the FT-IR spectrogram of Eriotinib malonate ERMO ULT-1
- Table 12A Characteristic Raman peaks of Eriotinib malonate ERMO ULT-1
- Figure 13 illustrates the X-Ray Powder Diffraction pattern of Eriotinib malonate ERMO ULT-2
- Figure 14 illustrates the X-Ray Powder Diffraction pattern of Eriotinib L-lactate ERLA ULT-1
- Figure 15A illustrates the high resolution X-Ray Powder Diffraction pattern of Eriotinib succinate ERSC ULT-1
- Figure 15B illustrates the DSC thermogram of Eriotinib succinate ERSC ULT-1
- Figure 15C illustrates the TGA thermogram of Eriotinib succinate ERSC ULT-1
- Figure 5D illustrates the TGA thermogram (top) and MS spectrum (bottom) of Eriotinib succinate ERSC ULT-1
- Figure 15E illustrates the Raman spectrogram of Eriotinib succinate ERSC ULT-1
- Figure 15F illustrates the FT-IR spectrogram of Eriotinib succinate ERSC ULT-1
- Figure 16 illustrates the X-Ray Powder Diffraction pattern of Eriotinib succinate ERSC ULT-2
- Figure 7 illustrates the X-Ray Powder Diffraction pattern of Eriotinib succinate ERSC ULT-3
- Figure 18 illustrates the X-Ray Powder Diffraction pattern of Eriotinib succinate ERSC ULT-4
- Figure 19A illustrates the X-Ray Powder Diffraction pattern of Eriotinib free base
- Figure 19B illustrates the DSC thermogram of Eriotinib free base
- FIG. 19C illustrates the TGA thermogram of Eriotinib free base
- Figure 19D illustrates the FT-IR spectrogram of Eriotinib free base
- Erlotinib ethanesulfonate may be prepared as described in examples 1 and 2. Erlotinib ethanesulfonate has been found also in 2 distinct polymorphs, depicted herein as ERET ULT-1— 2.
- the free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- the polymorphs ERET ULT-1 - 2 are characterized by the diffraction peaks found in the XRPD patterns shown below.
- the XRPD is essentially as shown in Figures 1A and 2A.
- ERET ULT-1 - 2 are found as anhydrous forms, as indicated by the results of the DSC and TGA analyses shown in Figures 1 B, 1C and 2B, 2C.
- polymorph ERET ULT-2 of Eriotinib ethanesulfonate is more soluble then the hydrochloric acid salt of Eriotinib as demonstrated by a comparative solubility determination in H20.
- the solubility is respectively 14.7 mg/mL, compared to 0.9 mg/mL for the hydrochloric acid salt of Eriotinib.
- Quantitative solubility determination was performed in water and / or buffers on Eriotinib ethanesulfonate salt at room temperature. Approximately 20 mg of Eriotinib ethanesulfonate salt was weighted in a 1.8 ml screw cap glass vial and 400 ⁇ liquid (water or buffers of pH 3, 5 and 6.8) was added.
- the vial was then closed and equilibrated for 24 h at room temperature under continuous stirring.
- the mother liquor was isolated from solids using a Tecan Genesis 200 liquid-handling robot.
- three independent dilutions (factor of 10, 50 and 200) were prepared with Tecan Genesis 200.
- the dilutions were measured by HPLC (wavelength 245 nm).
- two separate calibration curves for the HPLC (Agilent HP1100, UV-detector HP DAD) were made from two stock solutions of Eriotinib free base in water (stock concentrations 0.3 mg/ml and 0:5 mg/ml). The solubility was determined from the peak area from the HPLC chromatogram.
- Eriotinib isethionate may be prepared as described in examples 3 - 6. Eriotinib isethionate has been found also in 4 distinct polymorphs, depicted herein as ERIS ULT-1 - 4.
- Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group.
- the free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Eriotinib free base About 40 mg was solid dosed in a 1.8 mL glass vial.
- 2-hydroxy-ethanesulfonic acid isethionic acid
- solvent methanol, tetrahydrofuran, acetonitrile, 1,2-dimethoxyethane, 1 ,4-dioxane, 3-methyl-1-butanol, ethanol, ethylacetate, tert-butyl methyl ether, methanol/water, methylacetate
- solvent methanol, tetrahydrofuran, acetonitrile, 1,2-dimethoxyethane, 1 ,4-dioxane, 3-methyl-1-butanol, ethanol, ethylacetate, tert-butyl methyl ether, methanol/water, methylacetate
- the vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently the vials were allowed to cool to 5°C at rate of 1 °C/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor or if no solid was present, the solvent was evaporated. The supernatant solution was also evaporated. All resulting solids were dried and analyzed by XRPD. The polymorphs ERIS ULT-1 - 4 are characterized by the diffraction peaks found in the XRPD patterns shown below ( Figures 3A-5A, 6).
- ERIS ULT-1 and ERIS ULT-3 are found as hydrates, as indicated by the results of the TGA analyses shown in Figures 3C, 3D, 5B and 5C.
- ERIS ULT-2 is found as anhydrate, as indicated by the TGA results shown in Figures 4B, 4C.
- ERIS ULT-1 and ERIS ULT-2 of Eriotinib isethionate are more soluble then the hydrochloric acid salt of Eriotinib as demonstrated by a comparative solubility determination in H20.
- the solubility of ERIS ULT-1 and ERIS ULT-2 is respectively 1.7 mg/mL and 7.7 mg/mL compared to 0.9 mg mL for the hydrochloric acid salt of Eriotinib.
- Quantitative solubility determination was performed in water and / or buffers on Eiiotinib isethionate salt at room temperature.
- Erlotinib bromide may be prepared as described in examples 7-11 Erlotinib bromide has been found also in 5 distinct polymorphs, depicted herein as ERBR ULT-1 - 5.
- Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group.
- the free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Erlotinib free base was solid dosed in a 1.8 mL glass vial.
- the solvent methylacetate, methanol, tetrahydrofuran, acetonitrile, 1,2-dimethoxyethane, 1 ,4- dioxane, 3-methyl-1-butanol, ethanol, ethylacetate, water, acetone/water, 2,2,2- trifluoroethanol, tert-butyl methyl ether, ethanol water, methanol/water
- solvent methylacetate, methanol, tetrahydrofuran, acetonitrile, 1,2-dimethoxyethane, 1 ,4- dioxane, 3-methyl-1-butanol, ethanol, ethylacetate, water, acetone/water, 2,2,2- trifluoroethanol, tert-butyl methyl ether, ethanol water, methanol/water
- the final concentration of Erlotinib free base in the solvent was approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL).
- the vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5°C at rate of c/hr and kept at 5"C for 35-38 hr. Solid material was separated from the mother liquor or if no solid was present, the solvent was evaporated. The supernatant solution was also evaporated. All resulting solids were dried and analyzed by XRPD. The polymorphs ERBR ULT-1 - 5 are characterized by the diffraction peaks found in the XRPD patterns shown below ( Figures 7-11).
- ERBR ULT-1 and ERBR ULT-3 are found as anhydrate forms, as indicated by the results of the TGA analyses shown in Figures 7C, 9B.
- Polymorph ERBR ULT-1 of Erlotinib bromide is more soluble then the hydrochloric acid salt of Erlotinib as demonstrated by a comparative solubility determination in H20.
- the solubility of ERBR ULT-1 is 2.1 mg/mL compared to 0.9 mg/mL for the hydrochloric acid salt of Erlotinib.
- Quantitative solubility determination was performed in water and / or buffers on Erlotinib bromide salt at room temperature. Approximately 20 mg of Erlotinib bromide salt was weighted in a 1.8 ml screw cap glass vial and 400 ⁇ liquid (water or buffers of pH 3, 5 and 6.8) was added. The vial was then closed and equilibrated for 24 h at room temperature under continuous stirring. The mother liquor was isolated from solids using a Tecan Genesis 200 liquid-handling robot. Subsequently three independent dilutions (factor of 10, 50 and 200) were prepared with Tecan Genesis 200. The dilutions were measured by HPLC (wavelength 245 nm).
- Erlotinib malonate may be prepared as described in examples 12, 13 Erlotinib malonate has been found also in 2 distinct polymorphs, depicted herein as ERMO ULT-1 in anhydrate form and ERMO ULT-2.
- Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Erlotinib free base About 40 mg was solid dosed in a 1.8 mL glass vial. To the free base malonic acid was added in a ratio of 1.1 - 1.4 with respect to the free base of Erlotinib Subsequently, solvent ⁇ methylacetate, acetonitrile, ethanol/water, methanol water, tetrahydrofuran/water, acetonitrile water, methanol, acetone/water, 1 ,4- dioxane) was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL) of Erlotinib free base.
- the vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5°C at rate of 1°C/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor or if no solid was present, the solvent was evaporated. The supernatant solution was also evaporated. All resulting solids were dried and analyzed by XRPD.
- the polymorphs ER O ULT-1 - 2 are characterized by the diffraction peaks found in the XRPD patterns shown below.
- the XRPD is essentially as shown in Figures 12A, 13.
- polymorph ERMO ULT-1 of Erlotinib malonate is more soluble then the hydrochloric acid salt of Erlotinib as demonstrated by a comparative solubility determination in H20.
- the solubility is 1.6 mg/mL compared to 0.9 mg/mL for the hydrochloric acid salt of Erlotinib.
- Quantitative solubility determination was performed in water and / or buffers on Erlotinib malonate salt at room temperature. Approximately 20 mg of Erlotinib malonate salt was weighted in a 1.8 ml screw cap glass vial and 400 ⁇ liquid (water or buffers of pH 3, 5 and 6.8) was added. The vial was then closed and equilibrated for 24 h at room temperature under continuous stirring. The mother liquor was isolated from solids using a Tecan Genesis 200 liquid-handling robot. Subsequently three independent dilutions (factor of 10, 50 and 200) were prepared with Tecan Genesis 200. The dilutions were measured by HPLC (wavelength 245 nm).
- Erlotinib L-lactate may be prepared as described in example 14 Erlotinib L-lactate has been found also in 1 distinct polymorph, depicted herein as ERLA ULT-1.
- Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group.
- the free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- About 40 mg of Eriotinib free base was solid dosed in a 1.8 mL glass vial.
- Lactic acid was added in a ratio of 1.2 - 6.1 with respect to the free base of Eriotinib Subsequently, solvent (methyiacetate, 1 ,2-dimethoxyethane, 3-methyl-1-butanol, ethanol, ethylacetate) was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL) of Eriotinib free base.
- the vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5°C at rate of rc/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor or if no solid was present, the solvent was evaporated. The supernatant solution was also evaporated. All resulting solids were dried and analyzed by XRPD.
- the polymorph ERLA ULT-1 is characterized by the diffraction peaks found in the XRPD patterns shown below.
- the XRPD is essentially as shown in Figure 20.
- Quantitative solubility determination was performed in water and / or buffers on Eriotinib L-lactate salt at room temperature. Approximately 20 mg of Eriotinib L-lactate salt was weighted in a 1.8 ml screw cap glass vial and 400 ⁇ liquid (water or buffers of pH 3, 5 and 6.8) was added. The vial was then closed and equilibrated for 24 h at room temperature under continuous stirring. The mother liquor was isolated from solids using a Tecan Genesis 200 liquid-handling robot. Subsequently three independent dilutions (factor of 10, 50 and 200) were prepared with Tecan Genesis 200. The dilutions were measured by HPLC (wavelength 245 nm).
- Eriotinib succinate may be prepared as described in example 15-18. Eriotinib succinate has been found also in 4 distinct polymorphs, depicted herein as ERSC ULT-1 - 4 in anhydrate and hydrate forms.
- Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- the vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5°C at rate of 1 °C/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor or if no solid was present, the solvent was evaporated. The supernatant solution was also evaporated. All resulting solids were dried and analyzed by XRPD.
- the polymorphs ERSC ULT-1 - 4 are characterized by the diffraction peaks found in the XRPD patterns shown below.
- the XRPD is essentially as shown in Figures 21-24.
- the solubility is 3.3 mg/mL, compared to ⁇ 0.01 mg/mL for the hydrochloric acid salt of Erlotinib.
- Quantitative solubility determination was performed in water and / or buffers on Erlotinib L-lactate salt at room temperature. Approximately 20 mg of Erlotinib L-lactate salt was weighted in a 1.8 ml screw cap glass vial and 400 ⁇ liquid (water or buffers of pH 3, 5 and 6.8) was added. The vial was then closed and equilibrated for 24 h at room temperature under continuous stirring. The mother liquor was isolated from solids using a Tecan Genesis 200 liquid-handling robot. Subsequently three independent dilutions (factor of 10. 50 and 200) were prepared with Tecan Genesis 200. The dilutions were measured by HPLC (wavelength 245 nm).
- the compounds of this present invention are potent inhibitors of the erbB family of oncogenic and prooncogenic protein tyrosine kinases such as epidermal growth factor receptor (EGFR), erbB2, HER3, or HER4 and thus are all adapted to therapeutic use as antiproliferative agents (e.g., anticancer) in mammals, particularly in humans.
- EGFR epidermal growth factor receptor
- erbB2 HER3, or HER4
- the compounds of the present invention are also inhibitors of angiogenests and/or vasculogenesis.
- the compounds of the present invention are useful in the prevention and treatment of a variety of human hyperproliferative disorders such as malignant and benign tumors of the liver, kidney, bladder, breast gastric, ovarian, colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic carcinomas, sarcomas, glioblastomas, head and neck, and other hyperplasic conditions such as benign hyperplasia of the skin (e.g., psoriasis) and benign hyperplasia of the prostate (e.g., BPH).
- benign hyperplasia of the skin e.g., psoriasis
- BPH benign hyperplasia of the prostate
- a compound of the present invention may possess activity against a range of leukemias and lymphoid malignancies.
- the compounds of the present invention may also be useful in the treatment of additional disorders in which aberrant expression ligand receptor interactions or activation or signaling events related to various protein tyrosine kinases are involved.
- Such disorders may include those of neuronal, glial, astrocytal, hypothalamic, glandular, macrophagal, epithelial, stromal, or blastocoelic nature in which aberrant function, expression, activation or signaling of the erbB tyrosine kinases are involved.
- the compounds of the present invention may have therapeutic utility in inflammatory, angiogenic and immunologic disorders involving both identified and as yet unidentified tyrosine kinases that are inhibited by the compounds of the present invention.
- Administration of the compounds of the present invention can be effected by any method that enables delivery of the compounds to he site of action. These methods include oral routes intraduodenal routes, parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular and infusion), topical, and rectal administration.
- the amount of the active compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration and the judgment of the prescribing physician. However, an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg kg/day, in single or divided doses.
- a 70 kg human this would amount to about 0.0S to about 7 g/day, preferably about 0.2 to about 2.5 g/day.
- dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effects provided that such larger doses are first divided into several smaller doses by administration throughout the day.
- the active compound may be applied as a sole therapy or may involve one or more other antitumor substances, for example those selected from, for example, mitotic inhibitors.
- vinblastine For example vinblastine; alkylating agents, for example cis-platin, carboplatin and cyclophosphamide; antimetabolites, for example 5-fuorouracil, cytosine arabinoside and hydroxyurea, or, for example, one of the preferred antimetabolites disclosed in European patent Application No.
- alkylating agents for example cis-platin, carboplatin and cyclophosphamide
- antimetabolites for example 5-fuorouracil, cytosine arabinoside and hydroxyurea, or, for example, one of the preferred antimetabolites disclosed in European patent Application No.
- the pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet capsule, pill, powder, sustained release formulations, solution, suspension for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
- the pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages.
- the pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjutants, etc.
- Exemplary parenteral administration forms include solutions or suspensions of the active compounds in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions.
- Such dosage forms can be suitably buffered, if desired.
- suitable pharmaceutical carriers include inert diluents or fillers, water and various organic solvents.
- the pharmaceutical compositions may, if desired, contain additional ingredients such as flavorings, binders, excipients and the like.
- excipients such as citric acid
- various disintegrant such as starch, alginic acid and certain complex silicates
- binding agents such as sucrose, gelatin and acacia.
- lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes.
- Solid compositions of a similar type may also be employed in soft and hard filled gelatin capsules.
- Preferred materials include lactose or milk sugar and high molecular weight polyethylene glycols.
- the active compound herein may be combined with various sweetening or flavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, ethanoi, propylene glycol, glycerin, or combinations thereof.
- diluents such as water, ethanoi, propylene glycol, glycerin, or combinations thereof.
- XRPD patterns were obtained using a T2 high-throughput XRPD set-up by
- the plates were mounted on a Bruker GADDS diffractometer equipped with a Hi-Star area detector.
- the XRPD platform was calibrated using Silver Behenate for the long d-spacings and Corundum for the short d spacings.
- the High resolution powder patterns were collected on the D8 Advance system in the Brag-Brentano geometry equipped with LynxEye solid state detector.
- the patterns were collected in various 28 ranges, starting from about 2 4 °2 ⁇ until about 60-65 °28, with a step in the ragne of 0.04-0.16 °2 ⁇ without further processing.
- AH patterns were taken at Room Temperature, approximately 295K.
- Suitable single crystals were selected and glued to a glass fibre, which was then mounted on an X-ray diffraction goniometer. X-ray diffraction data were collected for these crystals at a temperature of 120K and at room temperature, using a KappaCCD system and MoKO radiation, generated by a FR590 X-ray generator (Bruker Nonius, Delft, The Netherlands).
- Unit-cell parameters and crystal structures were determined and refined using the software package aXus.
- Mass loss due to solvent or water loss from the crystals was determined by TGA SDTA. Monitoring of the sample weight, during heating in a TGA SDTA851e instrument (Mettler-Toledo GmbH, Switzerland), resulted in a weight vs. temperature curve. The TGA SDTA851e was calibrated for temperature with indium and aluminium. Samples were weighed into 100 microliter aluminium crucibles and sealed. The seals were pin-holed and the crucibles heated in the TGA from 25°C to 300°C at a heating rate of 20°C/min. Dry N2 gas is used for purging. Melting point determinations based on DSC have a variability of +/- 2.0 degrees Celsius, preferably 1.0 degrees Celsius.
- the Raman spectra were collected with a Raman microscope mW (Kaiser Opticals Inc) at 0.96 cm-1 resolution using a laser of 780 nm and a power output of 100. Eriotinib free base
- Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group.
- the free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art. Dry solid was analyzed by XRPD and additional analytical methods. Analytical data are presented in Figures 19A - 19D.
- Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group.
- the free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Eriotinib free base was weighted in a 50 mL glass reactor in the Mettler Toledo MultiMax MT device equipped with mechanical stirring. Ethylacetate was added to a final concentration of approximately 50 mg/mL of Eriotinib free base. Ethanesuifonic acid was added drop wise in a ratio of 1.1 with respect to the free base of Eriotinib to the above reaction mass under stirring with a speed of 200 rpm. The reactor was heated from rT to 60°C with a rate of 1°C/min and kept at 60°C for 60 minutes. Subsequently reactor was allowed to cool to 5°C at rate of 1 °C hr and kept at 5°C for 35- 38 hr.
- the free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Solid material was obtained by evaporation.
- the solids were dried at 20 -25 °C at 200 mbar for approximately 1 day and additionally at 40°C and 200 mbar for about 4 - 5 h. Dry solid was analyzed by XRPD and additional analytical methods. Analytical data are presented in Figures 2A - 2E.
- Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group.
- the free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group.
- the free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Erlotinib free base was solid dosed in a 1.8 ml_ glass vial.
- 2-hydroxy-ethanesulfonic acid isethionic acid
- ethylacetate was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL) of Erlotinib free base.
- the vials were sealed and heated from rT to 60 e C with a rate of 10°C/min and kept at 60°C for 60 minutes.
- the free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Erlotinib free base About 40 mg was solid dosed in a 1.8 mL glass vial. To the free base 2-hydroxy-ethanesulfonic acid (isethionic acid) was added in a ratio of 1.2 with respect to the free base of Erlotinib. Subsequently, methylacetate was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL) of Erlotinib free base. The vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes.
- 2-hydroxy-ethanesulfonic acid isethionic acid
- methylacetate was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL) of Erlotinib free base.
- the vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes.
- the free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Erlotinib free base About 40 mg was solid dosed in a 1.8 mL glass vial. To the free base 2-hydroxy-ethanesulfonic acid (isethionic acid) was added in a ratio of 1.2 with respect to the free base of Erlotinib. Subsequently, methylacetate was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL) of Erlotinib free base. The vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes.
- 2-hydroxy-ethanesulfonic acid isethionic acid
- methylacetate was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL) of Erlotinib free base.
- the vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes.
- Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group.
- the free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- About 1 g of Erlotinib free base was weighted in a 50 mL glass reactor in the Mettler Toledo MultiMax T device equipped with mechanical stirring.
- Ethylacetate was added to a final concentration of approximately 50 mg/mL of Erlotinib free base.
- 48 % of hydrobromic acid in ACS reagent was added drop wise in a ratio of 1.1 with respect to the free base of Erlotinib to the above reaction mass under stirring with a speed of 200 rpm.
- the reactor was heated from rT to 60°C with a rate of 1 0 C/min and kept at 60X for 60 minutes. Subsequently the reactor was allowed to cool to 5°C at rate of rc/hr and kept at 5°C for 35-38 hr. Stirring speed during the temperature profile was 300 rpm. Solid material was obtained by filtration under vacuum with a 5 ⁇ filter. The solids were dried at ,20 -25 °C at 200 mbar for approximately 1 day and additionally at 40°C and 200 mbar for about 4 - 5 h. Dry solid was analyzed by XRPD and additional analytical methods. Analytical data are presented in Figures 7A - 7F.
- the free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Erlotinib free base was solid dosed in a 1.8 mL glass vial.
- To the free base 48 % hydrobromic acid In ACS reagent was added together with acetone/water 50:50 in a ratio of 1.1 - 1.2 with respect to the free base of Erlotinib.
- the final concentration of Erlotinib free base in the solvent was approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL).
- the vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5°C at rate of 1 °C/hr and kept at 5°C for 35-38 hr.
- Solid material was separated from the mother liquor and dried at 20 -25 °C at 200 mbar for at least 1 day and up till 6 days. If remaining solid was still wet further drying was done at 20-25 °C at 5 mbar until sample was completely dry as judged by visual inspection. Dry solid was analyzed by XRPD ( Figure 8).
- Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group.
- the free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Eriotinib free base was solid dosed in a 1.8 mL glass vial.
- To the free base 48 % hydrobromic acid in ACS reagent was added together with methanol water 50:50 in a ratio of 1.1 with respect to the free base of Eriotinib.
- the final concentration of Eriotinib free base in the solvent was approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL).
- the vials were sealed and heated from rT to 60 e C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5°C at rate of 1 "C/hr and kept at 5°C for 35-38 hr.
- Solid material was separated from the mother liquor and dried at 20 -25 °C at 200 mbar for at least 1 day and up till 6 days. If remaining solid was still wet further drying was done at 20-25 °C at 5 mbar until sample was completely dry as judged by visual inspection. Dry solid was analyzed by XRPD ( Figure 9A).
- Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group.
- the free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Eriotinib free base was solid dosed in a 1.8 mL glass vial.
- To the free base 48 % hydrobromic acid in ACS reagent was added together with methanol in a ratio of 1.1 with respect to the free base of Eriotinib.
- the final concentration of Eriotinib free base in methanol was approximately 50 mg mL (range of 48.8 - 52.9 mg/mL).
- the vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5°C at rate of 1°C/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor.
- Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group.
- the free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Eriotinib free base was solid dosed in a 1.8 mL glass vial.
- To the free base 48 % hydrobromic acid in ACS reagent was added together with methanol in a ratio of 1.1 with respect to the free base of Eriotinib.
- the final concentration of Eriotinib free base in methanol was approximately 50 mg/mL (range of 48.8 - 52.9 mg mL).
- the vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5 e C at rate of 1°C/hr and kept at 5°C for 35-38 hr.
- Solid material was separated from the mother liquor.
- the solvent from the mother liquor was evaporated and the remaining solid was dried at 20 -25 °C at 200 mbar for at least 1 day and up till 6 days. If remaining solid was still wet further drying was done at 20-25 °C at 5 mbar until sample was completely dry as judged by visual inspection. Subsequently, the solids were exposed to 40°C and 75% relative humidity for 48 h and re-analyzed by XRPD ( Figure 11).
- Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group.
- the free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Eriotinib free base was weighted in a 50 mL glass reactor in the Mettler Toledo Multi ax MT device equipped with mechanical stirring.
- malonic acid was added in a ratio of 1.1 with respect to the free base of Eriotinib.
- ethanol/water 50:50 was added to a final concentration of approximately 50 mg/mL of Eriotinib free base.
- the reactor was heated from rT to 60°C with a rate of c/min and kept at 60°C for 60 minutes. Subsequently the reactor was allowed to cool to 5°C at rate of TC/hr and kept at 5°C for 35-38 hr. Stirring speed during the temperature profile was 300 rpm.
- Solid material was obtained by filtration under vacuum with a 5 ⁇ filter.
- the solids were dried at 20 -25 °C at 200 mbar for approximately 1 day and additionally at 40°C and 200 mbar for about 4 - 5 h. Subsequently, the solids were dispensed in water and the resulting slurry was stirred at room temperature for at least 1 day and up till 5 days.
- Solid material was separated from water, dried as mentioned above and analyzed by XRPD and additional analytical methods. Analytical data are presented in Figures 12A - 12F.
- Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group.
- the free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Eriotinib free base About 40 mg was solid dosed in a 1.8 mL glass vial. To the free base malonic acid was added in a ratio of 1.1 with respect to the free base of Eriotinib Subsequently, methanol/water 50:50 was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL) of Eriotinib free base. The vial was sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently the vial was allowed to cool to 5°C at rate of 1°C/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor.
- Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group.
- the free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Eriotinib free base About 40 mg was solid dosed in a 1.8 mL glass vial.
- Lactic acid was added in a ratio of 1.2 with respect to the free base of Eriotinib
- methylacetate was added to a final concentration of approximately 50 mg mL (range of 48.8 - 52.9 mg/mL) of Eriotinib free base.
- the vial was sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5°C at rate of 1°C/hr and kept at 5°C for 35- 38 hr.
- Solid material was separated from the mother liquor and dried at 20 -25 °C at 200 mbar for at least 1 day and up till 6 days. If remaining solid was still wet further drying was done at 20-25 °C at 5 mbar until sample was completely dry as judged by visual inspection.
- the XRPD pattern is presented in Figure 14.
- Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group.
- the free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Eriotinib free base was weighted in a 50 mL glass reactor in the ettler Toledo ultiMax T device equipped with mechanical stirring.
- succinic acid was added in a ratio of 1.1 with respect to the free base of Eriotinib.
- ethanol/water 50:50 was added to a final concentration of approximately 50 mg/mL of Eriotinib free base.
- the reactor was heated from rT to 60°C with a rate of 1°C/min and kept at 60°C for 60 minutes. Subsequently the reactor was allowed to cool to 5°C at rate of 1°C/hr and kept at 5"C for 35-38 hr.
- Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group.
- the free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Eriotinib free base was solid dosed in a stainless steel vial.
- succinic acid was added in a ratio of 1.1 with respect to the free base of Eriotinib.
- about 5 ⁇ - of water was added and the vial was sealed and shaken for at least 20 minutes and up till 90 minutes at a frequency of 30 s " ⁇ Solid material was analyzed by XRPD ( Figure 16).
- the free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Erlotinib free base was solid dosed in a 1.8 mL glass vial.
- succinic acid was added in a ratio of 1.1 with respect to the free base of Erlotinib.
- ethanol was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL) of Erlotinib free base.
- the vial was sealed and heated from rT to 60°C with a rate of 10 e C/min and kept at 60X for 60 minutes. Subsequently vial was allowed to cool to 5°C at rate of 1°C/hr and kept at 5°C for 35-38 hr.
- Solid material was separated from the mother liquor and dried at 20 -25 °C at 200 mbar for at least 1 day and up till 6 days. If remaining solid was still wet further drying was done at 20-25 °C at 5 mbar until sample was completely dry as judged by visual inspection.
- the XRPD pattern is presented in Figure 17.
- Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group.
- the free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
- Erlotinib free base About 40 mg was solid dosed in a 1.8 mL glass vial. To the free base succinic acid was added in a ratio of 1.1 with respect to the free base of Erlotinib. Subsequently, 1 ,2-dimethoxyethane was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg mL) of Erlotinib free base. The vial was sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vial was allowed to cool to 5°C at rate of TC/hr and kept at 5°C for 35-38 hr.
- Solid material was separated from the mother liquor and dried at 20 -25 °C at 200 mbar for at least 1 day and up till 6 days. If remaining solid was still wet further drying was done at 20-25 °C at 5 mbar until sample was completely dry as judged by visual inspection.
- the XRPD pattern is presented in Figure 18.
- Efficiency of extraction is determined by comparison by spiking rat plasma samples with known amounts of erlotinib.
- concentration of erlotinib is quantified in each sample by means of LC-MS-MS against a calibration curve.
- the results of the comparative pharmacokinetic are presented. From the PK data bioequivalency of the erlotinib sold forms to the mesylate and/or chloride salt of erlotinib can be determined.
- erlotinib The effects of food on the pharmacokinetics of erlotinib are investigated.
- 150 mg of erlotinib either the mesylate salt, the hydrochloride salt or the solid forms described herein are administered under either fasting or fed conditions.
- the area under the plasma concentration-time curve is determined by the geometric mean ratio (GMR) observed under fed or fasted conditions.
- identical doses of erlotinib, either the mesylate salt, the hydrochloride salt or the solid forms described herein are administered daily for 8 days, either 7 days of fasting followed by feeding on day 8, or the reverse sequence.
- the plasma concentration-time curve is determined to determine the food effect of the various erlotinib forms.
Abstract
The present invention relates to novel ethanesulfonate, isethionate, bromide, malonate, L-lactate, and succinate salts and polymorphs thereof of N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine (Erlotinib). The invention also relates to pharmaceutical compositions containing Erlotinib ethanesulfonate, isethionate, bromide, malonate, L-lactate, succinate salts and to the methods of treating hyperproliferative disorders such as cancer, by administering the Erlotinib salts.
Description
Title: NOVEL N-{3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4- QUINAZOLINA 1NE SALTS
Field of the Invention
The present invention relates to novel salts and polymorphs thereof of N-(3- ethynylphenylamino)-6,7-bis{2-methoxyethoxy)-4-quinazolinamine (Erlotinib). The invention also relates to pharmaceutical compositions containing Erlotinib salts and to the methods of treating hyperproliferative disorders such as cancer, by administering Erlotinib salts.
Background of the invention
The present invention relates to novel salts of Erlotinib and polymorphs of theses salts. This quinazolamine compounds are useful in the treatment of hyperproliferative disorders such as cancers in mammals.
United States patent number 5,747,498 filed May 28, 1996, refers to Erlotinib hydrochloride which, the patent application discloses, is an inhibitor of the erbB family of oncogenic and protooncogenic protein tyrosine kinases, such as the epidermal growth factor receptor (EGFR), and is therefore useful for the treatment of proliferative disorders such as cancers in humans. United States patent number 6,706,721, filed April 08, 1999 refers to Erlotinib mesylate salt. US patent publication 2002/006,443 discloses the solubility of the mesylate salt of Erlotinib being in the range of approximately 30 pg/mL to 100 pg/mL. The hydrochloric and mesylate compound have very limited solubility in aqueous compositions which limits their bioavailability and gives rise to an undesirable strong food effect. Limited solubility also limits the dosing route and formulation to a solid oral dosage form. However mesylates have an inherent problem in the way that a toxic impurity in the form of ethyl methanesulfonate can be formed in certain circumstances.
Hence there remains a need for Erlotinib based compounds that overcome the above described disadvantages. One advantage of the novel salts is that they are all more soluble in aqueous compositions than the above mentioned hydrochloride compound, and thus the novel salts of the present invention will posses increased
bioavailability, a reduction of the food effect and can be formulated for possible dosing routes. Furthermore, the toxic effect of ethyl methanesulfonate can be avoided.
Summary of the invention
The present inventors have found different salts and/or solid forms of Eriotinib which are useful for the treatment of proliferative disorders. It has been found that these salts and solid forms possess certain advantages over the prior art hydrochloride and mesylate compounds. It has been found that providing the novel salts in crystalline from provides for an enhanced stability until administration as a liquid and may be easier I the purification step at the end of the synthesis process. It has been found that the salts of the present invention are more soluble in aqueous compositions than the above mentioned hydrochloride, and thus the novel salts of the present invention will posses increased bioavailability, a reduction of the food effect and can be formulated for possible dosing routes. In particular, the invention relates to Eriotinib ethanesulfonate, isethionate, bromide, malonate, L-iactate and succinate in anhydrous and hydrated forms and polymorphic forms thereof.
Detailed Description of the Invention
The present invention relates to anhydrous and hydrated salts of Eriotinib.
One embodiment of the present invention relates to the ethanesulfonate salt of
Eriotinib.
Another embodiment of the present invention relates to the isethionate salt of Eriotinib.
Another embodiment of the present invention relates to the bromide salt of Eriotinib.
Another embodiment of the present invention comprises the malonate salt of Eriotinib.
Another embodiment of the present invention comprises the L-lactate salt of Eriotinib.
Another embodiment of the present invention comprises the succinate salt of Erlotinib.
The invention further relates to a pharmaceutical composition for the treatment of hyperproliferative disorder, specifically non-small cell lung cancer and bronchioalveolar cancer, in a mammal, including a human, which comprises a therapeutically effective amount of Erlotinib ethanesulfonate, isethionate, bromide, malonate, L-lactate and succinate and a pharmaceutical acceptable carrier. In one embodiment, said pharmaceutical composition is for the treatment of cancers.
The invention also relates to a pharmaceutical composition for the treatment of pancreatitis or kidney disease (including proliferative glomerulonephritis and diabetes- induced renal disease) in a mammal, including a human, which comprises a therapeutically effective amount of Erlotinib ethanesulfonate, isethionate, bromide, malonate, L-lactate and succinate and a pharmaceutical acceptable carrier.
The invention also relates to a pharmaceutical composition for the prevention of blastocyte implantation in a mammal, including a human, which comprises a therapeutically effective amount of Erlotinib ethanesulfonate, isethionate, bromide, malonate, L-lactate and succinate salt and a pharmaceutical acceptable carrier.
The invention also relates to a pharmaceutical composition for treating a disease related to vasculogenesis or angiogenesis in a mammal, including a human, which comprises a therapeutically effective amount of Erlotinib ethanesulfonate, isethionate, bromide, malonate, L-lactate and succinate salt and a pharmaceutical acceptable earner. In one embodiment, said pharmaceutical composition is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, skin diseases such as psoriasis, eczema, and scleroderma, diabetes, diabetes retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
The invention also relates to a method of treating hyperproliferative disorder in a mammal, including a human, which comprises administering to said mammal a therapeutically effective amount of Erlotinib ethanesulfonate, isethionate, bromide, malonate, L-factate and succinate salt. In one embodiment said method relates to the treatment of cancer such as brain, lung, squamous cell, bladder, gastric, pancreatic,
breast, neck, head, renal (such as kidney), ovarian, prostate, colorectal, oesophageal, gynecological or thyroid cancer. In another embodiment, said pharmaceutical composition is for the treatment of non-cancerous hyperproliferative disorder such being benign hyperplasia of the skin (e.g. psoriasis) or prostate (e.g. benign prostatic hypertrophy (BPH)).
The invention also relates to a method of treatment of a hyperproliferative disorder in a mammal, including a human, which comprises administering to said mammal a therapeutically effective amount of Erlotinib ethanesulfonate, isethionate, bromide, malonate, L-lactate and succinate salt, optionally in combination with an anti- tumor agent selected from the group of mitotic inhibitors, alkylating agents, antimetabolites, intercalating agents, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, and anti- androgens.
Patients that can be treated with Erlotinib ethanesulfonate, isethionate, bromide, malonate, L-lactate and succinate salt according to the methods of this invention include, for example, patients that have been diagnosed as having psoriasis, BPH, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, ovarian cancer, rectal cancer, cancer of he anal region, stomach cancer, colon cancer, breast cancer, gynecologic tumors (e.g., uterine sarcomas, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of he cervix, carcinoma of the vagina or carcinoma of the vulva), Hodgkin's disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system (e.g., cancer of the thyroid, parathyroid or adrenal glands), sarcomas of soft tissues, cancer of he urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, solid tumors of childhood, lymphatic lymphomas, cancer of the bladder, cancer of the kidney or ureter (e.g." renal call carcinoma, carcinoma of the renal pelvis), or neoplasms of the central nervous system (e.g. primary CNS lymphoma, spinal axis tumors, brainstem gliomas or pituitary adenomas). Brief description of the Figures and Tables
Figure 1A illustrates the high resolution X-Ray Powder Diffraction pattern of Erlotinib ethanesulfonate ERET ULT-1
Figure 1B illustrates the DSC thermogram of Erlotinib ethanesulfonate ERET ULT-1
Figure 1C illustrates the TGA thermogram of Erlotinib ethanesulfonate ERET ULT-1
Figure 2A illustrates the high, resolution X-Ray Powder Diffraction pattern of Erlotinib ethanesulfonate ERET ULT-2
Figure 2B illustrates the DSC thermogram of Erlotinib ethanesulfonate ERET ULT-2
Figure 2C illustrates the TGA thermogram of Erlotinib ethanesulfonate ERET ULT-2
Figure 2D illustrates the Raman spectrogram of Erlotinib ethanesulfonate ERET ULT-2
Figure 2E illustrates the FT-IR spectrogram of Erlotinib ethanesulfonate ERET ULT-2
Table 2A Characteristic Raman peaks of Erlotinib ethanesulfonate ERET ULT-2
Table 2B Characteristic FT-IR peaks of Erlotinib ethanesulfonate ERET ULT-2
Figure 3A illustrates the high resolution X-Ray Powder Diffraction pattern of Erlotinib isethionate ERIS ULT-1
Figure 3B illustrates the DSC thermogram of Erlotinib isethionate ERIS ULT-1
Figure 3C illustrates the TGA thermogram of Erlotinib isethionate ERIS ULT-1
Figure 3D illustrates the TGA thermogram (top) and MS spectrum (bottom) of Erlotinib isethionate ERIS ULT-1
Figure 3E illustrates the Raman spectrogram of Erlotinib isethionate ERIS ULT-1
Figure 3F illustrates the FT-IR spectrogram of Erlotinib isethionate ERIS ULT-1
Table 3A Characteristic Raman peaks of Erlotinib isethionate ERIS ULT-1
Table 3B Characteristic FT-IR peaks of Erlotinib isethionate ERIS ULT-1
Figure 4A illustrates the X-Ray Powder Diffraction pattern of Erlotinib isethionate ERIS ULT-2
Figure 4B illustrates the TGA thermogram of Erlotinib isethionate ERIS ULT-2
Figure 4C illustrates the TGA thermogram (top) and MS spectrum (bottom) of Erlotinib isethionate ERIS ULT-2
Figure 5A illustrates the X-Ray Powder Diffraction pattern of Erlotinib isethionate ERIS ULT-3
Figure 5B illustrates the TGA thermogram of Eriotinib isethionate ERIS ULT-3
Figure 5C illustrates the TGA thermogram (top) and MS spectrum (bottom) of Eriotinib isethionate ERIS ULT-3
Figure 6 illustrates the X-Ray Powder Diffraction pattern of Eriotinib isethionate ERIS ULT-4
Figure 7A illustrates the high resolution X-Ray Powder Diffraction pattern of Eriotinib bromide ERBR ULT-1
Figure 7B illustrates the DSC thermogram of Eriotinib bromide ERBR ULT-1
Figure 7C illustrates the TGA thermogram of Eriotinib bromide ERBR ULT-1
Figure 7D illustrates the Raman spectrogram of Eriotinib bromide ERBR ULT-1
Figure 7E illustrates the FT-IR spectrogram of Eriotinib bromide ERBR ULT-1
Table 7A Characteristic Raman peaks of Eriotinib bromide ERBR ULT-1
Table 7B Characteristic FT-IR peaks of Eriotinib bromide ERBR ULT-1
Figure 8 illustrates the X-Ray Powder Diffraction pattern of Eriotinib bromide ERBR ULT-2
Figure 9A illustrates the X-Ray Powder Diffraction pattern of Eriotinib bromide ERBR ULT-3
Figure 9B illustrates the TGA thermogram of Eriotinib bromide ERBR ULT-3
Figure 10 illustrates the X-Ray Powder Diffraction pattern of Eriotinib bromide ERBR ULT-4
Figure 11 illustrates the X-Ray Powder Diffraction pattern of Eriotinib bromide ERBR ULT-5
Figure 12A illustrates the high resolution X-Ray Powder Diffraction pattern of Eriotinib malonate ERMO ULT-1
Figure 12B illustrates the DSC thermogram of Eriotinib malonate ERMO ULT-1
Figure 12C illustrates the TGA thermogram of Eriotinib malonate ERMO ULT-1
Figure 12D illustrates the Raman spectrogram of Eriotinib malonate ERMO ULT-1
Figure 12E illustrates the FT-IR spectrogram of Eriotinib malonate ERMO ULT-1
Table 12A Characteristic Raman peaks of Eriotinib malonate ERMO ULT-1
Table 12B Characteristic FT-IR peaks of Eriotinib malonate ERMO ULT-1
Figure 13 illustrates the X-Ray Powder Diffraction pattern of Eriotinib malonate ERMO ULT-2
Figure 14 illustrates the X-Ray Powder Diffraction pattern of Eriotinib L-lactate ERLA ULT-1
Figure 15A illustrates the high resolution X-Ray Powder Diffraction pattern of Eriotinib succinate ERSC ULT-1
Figure 15B illustrates the DSC thermogram of Eriotinib succinate ERSC ULT-1
Figure 15C illustrates the TGA thermogram of Eriotinib succinate ERSC ULT-1
Figure 5D illustrates the TGA thermogram (top) and MS spectrum (bottom) of Eriotinib succinate ERSC ULT-1
Figure 15E illustrates the Raman spectrogram of Eriotinib succinate ERSC ULT-1
Figure 15F illustrates the FT-IR spectrogram of Eriotinib succinate ERSC ULT-1
Table 15A Characteristic Raman peaks of Eriotinib succinate ERSC ULT-1
Tabie 15B Characteristic FT-IR peaks of Eriotinib succinate ERSC ULT-1
Figure 16 illustrates the X-Ray Powder Diffraction pattern of Eriotinib succinate ERSC ULT-2
Figure 7 illustrates the X-Ray Powder Diffraction pattern of Eriotinib succinate ERSC ULT-3
Figure 18 illustrates the X-Ray Powder Diffraction pattern of Eriotinib succinate ERSC ULT-4
Figure 19A illustrates the X-Ray Powder Diffraction pattern of Eriotinib free base
Figure 19B illustrates the DSC thermogram of Eriotinib free base
Figure 19C illustrates the TGA thermogram of Eriotinib free base
Figure 19D illustrates the FT-IR spectrogram of Eriotinib free base
Table 19A Characteristic FT-IR peaks of Eriotinib free base
Erlotinib ethanesulfonate.
Erlotinib ethanesulfonate may be prepared as described in examples 1 and 2. Erlotinib ethanesulfonate has been found also in 2 distinct polymorphs, depicted herein as ERET ULT-1— 2.
Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical
Group. The free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 1 g of Erlotinib free base was weighted in a 50 mL glass reactor in the Mettler Toledo MultiMaxMT device equipped with mechanical stirring. The solvent (ethylacetate, water) was added to a final concentration of approximately 50 mg/mL of Erlotinib free base. Ethanesulfonic acid was added drop wise in a ratio of 1.1 with respect to the free base of Erlotinib to the above reaction mass under stirring with a speed of 200 rpm. The reactor was heated from rT to 60°C with a rate of 1°C/min and kept at 60°C for 60 minutes. Subsequently reactor was allowed to cool to 5°C at rate of 1 °C/hr and kept at 5°C for 35-38 hr. Stirring speed during the temperature profile was 300 rpm. Solid material was obtained by filtration under vacuum with a 5 μτη filter and/or by evaporation. The solids were dried at 20 -25 °C at 200 mbar for approximately 1 day and additionally at 40°C and 200 mbar for about 4 - 5 h. Dry solid was analyzed by XRPD.
The polymorphs ERET ULT-1 - 2 are characterized by the diffraction peaks found in the XRPD patterns shown below. The XRPD is essentially as shown in Figures 1A and 2A.
ERET ULT-1 - 2 are found as anhydrous forms, as indicated by the results of the DSC and TGA analyses shown in Figures 1 B, 1C and 2B, 2C.
5 13.16 L
6 16.17 L
7 18.94
8 20.62 L
9 21.76 L
10 23.82 L
11 25.32 L
L<40<M<60<H
ERET ULT-2
Peak table for SUD41
Peak Angle
(2Θ)
1 5.9 L
2 8.36 L
3 10.18 L
4 11.73 H
5 13.02 L
6 13.27 L
7 16.8 L
8 16.89 M
9 17.09 M
10 17.88 H
11 18.81 M
12 19.57 L
13 19.87 L
14 20.05 M
15 20.44 M
16 20.72 L
17 21.57 L
18 22.21 L
ERET ULT-2
Peak table for SUD41
Peak Angle
ID (2Θ)
19 23.62 L
20 23.98 H
21 24.72 M
22 25.16 L
23 25.38 L
24 25.72 L
25 26.01 L
26 26.29 L
27 26.73 H
28 27.84 L
29 28.15 L
30 28.93 L
31 29.56 L
32 30.06 L
33 30.49 L
34 31.09 L
35 31.72 L
36 32.77 L
37 33.94 L
38 34.22 L
39 34.62 L
40 36.38 L
L<35<M<60<H
It has been found that polymorph ERET ULT-2 of Eriotinib ethanesulfonate is more soluble then the hydrochloric acid salt of Eriotinib as demonstrated by a comparative solubility determination in H20. The solubility is respectively 14.7 mg/mL, compared to 0.9 mg/mL for the hydrochloric acid salt of Eriotinib.
Quantitative solubility determination was performed in water and / or buffers on Eriotinib ethanesulfonate salt at room temperature. Approximately 20 mg of Eriotinib ethanesulfonate salt was weighted in a 1.8 ml screw cap glass vial and 400 μΙ liquid (water or buffers of pH 3, 5 and 6.8) was added. The vial was then closed and equilibrated for 24 h at room temperature under continuous stirring. The mother liquor was isolated from solids using a Tecan Genesis 200 liquid-handling robot. Subsequently three independent dilutions (factor of 10, 50 and 200) were prepared with Tecan Genesis 200. The dilutions were measured by HPLC (wavelength 245 nm). Further, two separate calibration curves for the HPLC (Agilent HP1100, UV-detector HP DAD) were made from two stock solutions of Eriotinib free base in water (stock concentrations 0.3 mg/ml and 0:5 mg/ml). The solubility was determined from the peak area from the HPLC chromatogram.
Eriotinib isethionate.
Eriotinib isethionate may be prepared as described in examples 3 - 6. Eriotinib isethionate has been found also in 4 distinct polymorphs, depicted herein as ERIS ULT-1 - 4.
Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 40 mg of Eriotinib free base was solid dosed in a 1.8 mL glass vial. To the free base 2-hydroxy-ethanesulfonic acid (isethionic acid) was added in a ratio of 1.1 - 1.4 with respect to the free base of Eriotinib Subsequently, solvent (methanol, tetrahydrofuran, acetonitrile, 1,2-dimethoxyethane, 1 ,4-dioxane, 3-methyl-1-butanol, ethanol, ethylacetate, tert-butyl methyl ether, methanol/water, methylacetate) was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL) of Eriotinib free base. The vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently the vials were allowed to cool to 5°C at rate of 1 °C/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor or if no solid was present, the solvent was evaporated. The supernatant solution was also evaporated. All resulting solids were dried and analyzed by XRPD.
The polymorphs ERIS ULT-1 - 4 are characterized by the diffraction peaks found in the XRPD patterns shown below (Figures 3A-5A, 6). ERIS ULT-1 and ERIS ULT-3 are found as hydrates, as indicated by the results of the TGA analyses shown in Figures 3C, 3D, 5B and 5C. ERIS ULT-2 is found as anhydrate, as indicated by the TGA results shown in Figures 4B, 4C.
ERIS ULT-1
Peak table for SUD 26
Peak Angle
ID (2Θ)
1 7.31 L
2 7.43 M
3 7.65
4 8.3 M
5 11.37 L
6 11.8 L
7 12.61 L
8 14.81 L
9 15.06 L
10 15.91 M
11 16.09 L
12 16.4 L
13 16.66 L
14 20.26 M
15 20.58 M
16 20.92 L
17 21.84 L
18 22.06 L
19 22.24 L
20 22.6 M
21 22.8 M
22 23. 1 L
23 23.37 H
24 23.72 L
ERIS ULT-1
Peak table for SUD 26
Peak Angle
ID (2Θ)
25 24.47 L
26 24.9 H
27 25.78 L
28 26.27 H
29 27.11 H
30 27.65 L
31 28.55 L
32 29.09 L
33 29.58 L
34 30.41 L
35 30.94 L
L<40<M<60<H
ERIS ULT-2
Peak table for co 03.1 c : K8
Peak Angle
ID (28)
1 5.7 L
2 8.18 L
3 12.26 M
4 13.14 L
5 16.34 L
6 17.14 L
7 17.7 M
8 18.54 M
9 19.1 M
10 20.62 L
11 21.39 L
ERIS ULT-2
Peak table for co 03.1 c : K8
Peak Angle
ID (2Θ)
12 23.04 L
13 24.58 H
14 26.5 M
15 29.15 L
16 30.2 L
17 31.26 L
L<35< <60<H
ERIS ULT-3
Peak table for co 03.1 c : H8
Peak Angle
ID (2Θ)
1 5.38 L
2 6.54 H
3 7.3 M
4 13.38 L
5 14.48 L
6 15.63 L
7 17.86 L
8 19.18 L
9 19.58 L
10 20.54 L
11 21.35 L
12 21.9 L
13 22.83 L
14 24.31 L
15 25.05 L
16 26.02 M
ERIS ULT-3
Peak table for co 03.1 c : H8
Peak Angle
ID (2Θ)
17 27.22 L
18 28.52 L
19 29.57 L
L<40<M<60<H
The polymorphs ERIS ULT-1 and ERIS ULT-2 of Eriotinib isethionate are more soluble then the hydrochloric acid salt of Eriotinib as demonstrated by a comparative solubility determination in H20. The solubility of ERIS ULT-1 and ERIS ULT-2 is respectively 1.7 mg/mL and 7.7 mg/mL compared to 0.9 mg mL for the hydrochloric acid salt of Eriotinib.
Quantitative solubility determination was performed in water and / or buffers on Eiiotinib isethionate salt at room temperature. Approximately 20 mg of Erlotinib ethanesulfonate salt was weighted in a 1.8 ml screw cap glass vial and 400 μΙ liquid (water or buffers of pH 3, 5 and 6.8) was added. The vial was then closed and equilibrated for 24 h at room temperature under continuous stirring. The mother liquor was isolated from solids using a Tecan Genesis 200 liquid-handling robot. Subsequently three independent dilutions (factor of 10, 50 and 200) were prepared with Tecan Genesis 200. The dilutions were measured by HPLC (wavelength 245 nm). Further, two separate calibration curves for the HPLC (Agilent HP1100, UV-detector HP DAD) were made from two stock solutions of Erlotinib free base in water (stock concentrations 0.3 mg/ml and 0.5 mg/ml). The solubility was determined from the peak area from the HPLC chromatogram.
Erlotinib bromide.
Erlotinib bromide may be prepared as described in examples 7-11 Erlotinib bromide has been found also in 5 distinct polymorphs, depicted herein as ERBR ULT-1 - 5.
Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 40 mg of Erlotinib free base was solid dosed in a 1.8 mL glass vial. To the free base 48 % hydrobromic acid in ACS reagent was added together with the solvent (methylacetate, methanol, tetrahydrofuran, acetonitrile, 1,2-dimethoxyethane, 1 ,4- dioxane, 3-methyl-1-butanol, ethanol, ethylacetate, water, acetone/water, 2,2,2- trifluoroethanol, tert-butyl methyl ether, ethanol water, methanol/water) in a ratio of 1.1 - 1.2 with respect to the free base of Erlotinib. The final concentration of Erlotinib free base in the solvent was approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL). The vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5°C at rate of c/hr and kept at 5"C for 35-38 hr. Solid material was separated from the mother liquor or if no solid was present, the solvent was evaporated. The supernatant solution was also evaporated. All resulting solids were dried and analyzed by XRPD.
The polymorphs ERBR ULT-1 - 5 are characterized by the diffraction peaks found in the XRPD patterns shown below (Figures 7-11).
ERBR ULT-1 and ERBR ULT-3 are found as anhydrate forms, as indicated by the results of the TGA analyses shown in Figures 7C, 9B.
ERBR ULT-1
Peak table for SUD1
Peak Angle
ID (2Θ)
1 6.23 H
2 7.84 L
3 9.55 M
4 11.39 L
5 12.47 L
6 13.37 L
7 14.76 L
8 15.67 L
9 16.95 L
10 17.63 L
11 20.19 M
12 20.67 L
13 20.93 L
14 21.11 L
15 21.85 L
16 22.43 M
17 22.96 M
18 23.83 L
19 23.94 M
20 24.43 M
21 24.65 M
22 25.12 H
23 25.90 L
24 26.50 L
ERBR ULT-1
Peak table for SUD1
Peak Angle
ID (2Θ)
25 26.75 L
26 26.95 L
27 28.60 L
28 28.95 L
29 29.70 L
30 32.66 L
31 34.72 L
32 40.08 L
L<35<M<60<H
ERBR ULT-2
Peak table for co 03.1 c : L4
Peak Angle
ID (2Θ)
1 5.66 H
2 9.58 L
3 12.74 L
4 15.18 L
5 16.99 L
6 13.58 L
7 18.7 M
8 19.1 L
9 20.42 L
10 22.42 M
11 23.38 M
12 23.86 H
13 24.54 M
14 25.18 M
ERBR ULT-2
Peak table for co 03.1 c : L4
Peak Angle
ID (2Θ)
15 25.62
16 26.44 L
17 27.29 L
18 28.5 M
19 29.22 L
20 30.58 L
21 31.06 L
22 32.17 L
23 37.57 L
L<40<M<60<H
ERBR ULT-3
Peak table for co 03.2 c : K4
Peak Angle
ID (26)
1 6.26 H
2 7.78 L
3 9.3 M
4 13.33 L
5 15.5 L
6 16.74 L
7 18.17 L
8 18.66 L
9 19.7 M
10 20.5 L
11 21 L
12 22.06 M
13 22.94 H
ERBR ULT-3
Peak table for co 03.2 c : K4
Peak Angle
ID (2Θ)
14 23.9 M
15 24.34 M
16 24.98 M
17 26.34 M
18 28.26 M
19 28.87 L
20 29.37 L
21 30.49 L
22 30.99 L
23 32.04 L
24 33.29 L
25 34.1 L
26 35.09 L
27 36.77 L
28 38.14 L
29 40.15 L
L<35<M<60<H
ERBR ULT-4
Peak table for co 04.0 c : H5
Peak Angle
ID (2Θ)
1 5.9 H
2 8.14 L
3 11.3 L
4 11.66 M
5 12.68 L
6 16.31 L
ERBR ULT-4
Peak table for co 04.0 c : H5
Peak Angle
ID (2Θ)
7 17.9 L
8 18.87 . L
9 21.1 L
10 22.63 L
11 23.34 L
12 23.82 M
13 25.98
14 27.14 M
15 28.42 L
16 29.17 L
17 31.84 L
L<25<M<60<H
ERBR ULT-5
Peak table for co 04.1 c : H5
Peak Angle
ID (2Θ)
1 6.22 H
2 8.38 L
3 11.78 M
4 14.68 L
5 16.85 L
6 18.14 L
7 18.7 L
8 19.44 L
9 20.36 L
10 20.92 L
11 22.63 L
ERBR ULT-5
Peak table for co 04.1 c : H5
Peak Angle
ID (2Θ)
12 23.13 L
13 24.62 M
14 25.25 L
15 26.46 M
16 27.82 L
17 28.59 L
18 29.46 L
L<25<M<60<H
Polymorph ERBR ULT-1 of Erlotinib bromide is more soluble then the hydrochloric acid salt of Erlotinib as demonstrated by a comparative solubility determination in H20. The solubility of ERBR ULT-1 is 2.1 mg/mL compared to 0.9 mg/mL for the hydrochloric acid salt of Erlotinib.
Quantitative solubility determination was performed in water and / or buffers on Erlotinib bromide salt at room temperature. Approximately 20 mg of Erlotinib bromide salt was weighted in a 1.8 ml screw cap glass vial and 400 μΙ liquid (water or buffers of pH 3, 5 and 6.8) was added. The vial was then closed and equilibrated for 24 h at room temperature under continuous stirring. The mother liquor was isolated from solids using a Tecan Genesis 200 liquid-handling robot. Subsequently three independent dilutions (factor of 10, 50 and 200) were prepared with Tecan Genesis 200. The dilutions were measured by HPLC (wavelength 245 nm). Further, two separate calibration curves for the HPLC (Agilent HP1100, UV-detector HP DAD) were made from two stock solutions of Erlotinib free base in water (stock concentrations 0.3 mg ml and 0.5 mg/ml). The solubility was determined from the peak area from the HPLC chromatogram.
Erlotinib malonate.
Erlotinib malonate may be prepared as described in examples 12, 13 Erlotinib malonate has been found also in 2 distinct polymorphs, depicted herein as ERMO ULT-1 in anhydrate form and ERMO ULT-2.
Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 40 mg of Erlotinib free base was solid dosed in a 1.8 mL glass vial. To the free base malonic acid was added in a ratio of 1.1 - 1.4 with respect to the free base of Erlotinib Subsequently, solvent {methylacetate, acetonitrile, ethanol/water, methanol water, tetrahydrofuran/water, acetonitrile water, methanol, acetone/water, 1 ,4- dioxane) was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL) of Erlotinib free base. The vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5°C at rate of 1°C/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor or if no solid was present, the solvent was evaporated. The supernatant solution was also evaporated. All resulting solids were dried and analyzed by XRPD.
The polymorphs ER O ULT-1 - 2 are characterized by the diffraction peaks found in the XRPD patterns shown below. The XRPD is essentially as shown in Figures 12A, 13.
ERMO ULT-1
Peak table for SDU 25
Peak Angle
ID (2Θ)
1 6.68 H
2 8.85 L
3 9.31 L
4 12.07 L
5 13.29 L
6 15.98 L
7 16.78 L
8 17.43 L
9 18.91 M
10 19.36 M
11 20.17 L
ERMO ULT-1
Peak table for SDU 25
Peak Angle
ID (2Θ)
12 20.44 L
13 21.05 L
14 21.67
15 22.85 L
16 23.09 L
17 23.70 L
18 24.70 L
19 24.89 L
20 26.68 H
21 26.90 H
22 27.69 L
23 28.25
L<35<M<60<H
ERMO ULT-2
Peak table for co 11.1 c : H4
Peak Angle
ID (2Θ)
1 2.26 L
2 5.42 H
3 8.26 M
4 10.82 L
5 14.3 M
6 16.5 M
7 17.86 M
8 20.81 L
9 21.74 L
10 22.46 M
ERMO ULT-2
Peak table for co 1 .1 c . H4
Peak Angle
ID (28)
11 24.06 H
12 25.14 M
13 25.78 H
L<40<M<60<H
It has been found that polymorph ERMO ULT-1 of Erlotinib malonate is more soluble then the hydrochloric acid salt of Erlotinib as demonstrated by a comparative solubility determination in H20. The solubility is 1.6 mg/mL compared to 0.9 mg/mL for the hydrochloric acid salt of Erlotinib.
Quantitative solubility determination was performed in water and / or buffers on Erlotinib malonate salt at room temperature. Approximately 20 mg of Erlotinib malonate salt was weighted in a 1.8 ml screw cap glass vial and 400 μΙ liquid (water or buffers of pH 3, 5 and 6.8) was added. The vial was then closed and equilibrated for 24 h at room temperature under continuous stirring. The mother liquor was isolated from solids using a Tecan Genesis 200 liquid-handling robot. Subsequently three independent dilutions (factor of 10, 50 and 200) were prepared with Tecan Genesis 200. The dilutions were measured by HPLC (wavelength 245 nm). Further, two separate calibration curves for the HPLC (Agilent HP 1100, UV-detector HP DAD) were made from two stock solutions of Erlotinib free base in water (stock concentrations 0.3 mg/ml and 0.5 mg/ml). The solubility was determined from the peak area from the HPLC chromatogram.
Erlotinib L-lactate.
Erlotinib L-lactate may be prepared as described in example 14 Erlotinib L-lactate has been found also in 1 distinct polymorph, depicted herein as ERLA ULT-1.
Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 40 mg of Eriotinib free base was solid dosed in a 1.8 mL glass vial. To the free base Lactic acid was added in a ratio of 1.2 - 6.1 with respect to the free base of Eriotinib Subsequently, solvent (methyiacetate, 1 ,2-dimethoxyethane, 3-methyl-1-butanol, ethanol, ethylacetate) was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL) of Eriotinib free base. The vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5°C at rate of rc/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor or if no solid was present, the solvent was evaporated. The supernatant solution was also evaporated. All resulting solids were dried and analyzed by XRPD.
The polymorph ERLA ULT-1 is characterized by the diffraction peaks found in the XRPD patterns shown below. The XRPD is essentially as shown in Figure 20.
ERLA ULT-1
Peak table for co 22.0 c : J2
Peak Angle
ID (2Θ)
1 6.46 H
2 7.83 L
3 12.41 L
4 12.81 L
5 15.84 L
6 16.66 L
7 18.2 L
8 19.48 L
9 20:42 L
10 21.03 L
11 21.7 L
12 22.58 M
13 23.53 L
14 24.64 L
15 26.24 L
16 25.66 M
ERLA ULT-1
Peak table for co 22.0 c : J2
Peak Angle
ID (2Θ)
17 26.75 L
18 27.2 L
19 29.24 L
L<20<M<60<H
It has been found that ERLA ULT-1 polymorph of Eriotinib L-lactate is more soluble then the hydrochloric acid salt of Eriotinib as demonstrated by a comparative solubility determination in H20. The solubility is 14.9 mg/mL compared to 0.9 mg/mL for the hydrochloric acid salt of Eriotinib.
Quantitative solubility determination was performed in water and / or buffers on Eriotinib L-lactate salt at room temperature. Approximately 20 mg of Eriotinib L-lactate salt was weighted in a 1.8 ml screw cap glass vial and 400 μΙ liquid (water or buffers of pH 3, 5 and 6.8) was added. The vial was then closed and equilibrated for 24 h at room temperature under continuous stirring. The mother liquor was isolated from solids using a Tecan Genesis 200 liquid-handling robot. Subsequently three independent dilutions (factor of 10, 50 and 200) were prepared with Tecan Genesis 200. The dilutions were measured by HPLC (wavelength 245 nm). Further, two separate calibration curves for the HPLC (Agilent HP1100, UV-detector HP DAD) were made from two stock solutions of Eriotinib free base in water (stock concentrations 0.3 mg/ml and 0.5 mg/ml). The solubility was determined from the peak area from the HPLC chromatogram.
Eriotinib succinate.
Eriotinib succinate may be prepared as described in example 15-18. Eriotinib succinate has been found also in 4 distinct polymorphs, depicted herein as ERSC ULT-1 - 4 in anhydrate and hydrate forms.
Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 40 mg of Erlotinib free base was solid dosed in a 1.8 mL glass vial. To the free base succinic acid was added in a ratio of 0.9 - 1.9 with respect to the free base of Erlotinib Subsequently, solvent (2,2,2-trifluoroethanol, ethylacetate, water, ethanol water, methanol/water, acetone/water, acetonitrile/water, tetrahydrofuran water, methylacetate, methanol, tetrahydrofuran, acetonitrile, 1 ,4-dioxane, 3-methyl-1-butanol, ethanol, tert- butyl methyl ether) was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL) of Erlotinib free base. The vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5°C at rate of 1 °C/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor or if no solid was present, the solvent was evaporated. The supernatant solution was also evaporated. All resulting solids were dried and analyzed by XRPD.
In the case of polymorph ERSC ULT-2, about 50 mg of Erlotinib free base was solid dosed in a stainless steel vial. To the free base succinic acid was added in a ratio of 1.1 with respect to the free base of Erlotinib. Subsequently, about 5μL of solvent (2- propanol, isopropyl acetate, n-heptane, water) was added and the vials were sealed and shaken for at least 20 minutes and up till 90 minutes at a frequency of 30 s"1. Solid material was analyzed by XRPD.
The polymorphs ERSC ULT-1 - 4 are characterized by the diffraction peaks found in the XRPD patterns shown below. The XRPD is essentially as shown in Figures 21-24.
Peak table for SUD36
Peak Angle
(2Θ)
4 11.64 L
5 12.05 L
6 14.40 L
7 14.71 L
8 14.95 L
9 15.15 L
10 15.90 M
11 16.35 L
12 16.54 L
13 19.91 L
14 20.38 M
15 20.84 L
16 21.27 L
17 21.50 L
18 21.77 L
19 22.15 L
20 22.51 L
21 22.69 M
22 22.87 L
23 23.27 L
24 23.94 H
25 24.26 L
26 25.26 M
27 25.67 L
28 26.70 M
29 27.51 H
30 28.46 L
31 29.08 L
L<35<M<60<H
■ se AHI
ERSC ULT-2
Peak table for grc 06.4 c : L4
Peak Angle
ID (2Θ)
1 6.54 H
2 7.34 H
3 9.82 L
4 11.36 L
5 12.88 L
6 14.77 L
7 18.74 M
8 19.67 L
9 20.46 M
10 22.17 L
11 22.78 M
12 23.94 L
13 25.18 M
14 26.3 M
15 27.02 L
16 27.58 L
17 28.62 L
18 29.3 L
19 31.29 L
L<40<M<60<H
ERSC ULT-3
Peak table for co 07.0 c : C2
Peak Angle
ID (2Θ)
1 6.62 H
2 7.97 L
ERSC ULT-3
Peak table for co 07.0 c : C2
Peak Angle
ID (2Θ)
3 13.04 L
4 15.2 L
5 16.31 M
6 17.71 L
7 19.21 L
8 19.91 L
9 21.07 M
10 21.73 L
11 22.63 L
12 24.49 L
13 25.49
14 26.34
15 27.45 L
16 28.95 L
17 30.31 L
L<15<M<60<H
ERSC ULT-4
Peak table for co 16.0 c : G3
Peak Angle
ID (2Θ)
1 3.7 M
2 6.66
3 7.46 H
4 8.28 L
5 13.05 L
6 13.66 L
7 14.54 L
ERSC ULT-4
Peak table for co 16.0 c : G3
Peak Angle
ID (2Θ)
8 15.12 L
9 18.5 L
10 19.55 L
11 20.33 L
12 22.15 M
13 22.61 M
14 24.63
15 25.29 M
16 25.82 M
17 26.52 M
18 29.38 L
19 31.36 L
L<20<M<60<H
Polymorph ERSC ULT- of Erlotinib succinate is more soluble then the hydrochloric acid salt of Erlotinib as demonstrated by a comparative solubility determination in sodium dihydrogen phosphate buffer, pH=6.8. The solubility is 3.3 mg/mL, compared to <0.01 mg/mL for the hydrochloric acid salt of Erlotinib.
Quantitative solubility determination was performed in water and / or buffers on Erlotinib L-lactate salt at room temperature. Approximately 20 mg of Erlotinib L-lactate salt was weighted in a 1.8 ml screw cap glass vial and 400 μΙ liquid (water or buffers of pH 3, 5 and 6.8) was added. The vial was then closed and equilibrated for 24 h at room temperature under continuous stirring. The mother liquor was isolated from solids using a Tecan Genesis 200 liquid-handling robot. Subsequently three independent dilutions (factor of 10. 50 and 200) were prepared with Tecan Genesis 200. The dilutions were measured by HPLC (wavelength 245 nm). Further, two separate calibration curves for the HPLC (Agilent HP1100, UV-detector HP DAD) were made from two stock solutions of Erlotinib free base in water (stock concentrations 0.3 mg/ml and 0.5 mg/ml). The solubility was determined from the peak area from the HPLC chromatogram.
The compounds of this present invention are potent inhibitors of the erbB family of oncogenic and prooncogenic protein tyrosine kinases such as epidermal growth factor receptor (EGFR), erbB2, HER3, or HER4 and thus are all adapted to therapeutic use as antiproliferative agents (e.g., anticancer) in mammals, particularly in humans. The compounds of the present invention are also inhibitors of angiogenests and/or vasculogenesis. In particular, the compounds of the present invention are useful in the prevention and treatment of a variety of human hyperproliferative disorders such as malignant and benign tumors of the liver, kidney, bladder, breast gastric, ovarian, colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic carcinomas, sarcomas, glioblastomas, head and neck, and other hyperplasic conditions such as benign hyperplasia of the skin (e.g., psoriasis) and benign hyperplasia of the prostate (e.g., BPH). It is expected that a compound of the present invention may possess activity against a range of leukemias and lymphoid malignancies. The compounds of the present invention may also be useful in the treatment of additional disorders in which aberrant expression ligand receptor interactions or activation or signaling events related to various protein tyrosine kinases are involved. Such disorders may include those of neuronal, glial, astrocytal, hypothalamic, glandular, macrophagal, epithelial, stromal, or blastocoelic nature in which aberrant function, expression, activation or signaling of the erbB tyrosine kinases are involved. In addition, the compounds of the present invention may have therapeutic utility in inflammatory, angiogenic and immunologic disorders involving both identified and as yet unidentified tyrosine kinases that are inhibited by the compounds of the present invention.
Other methods for determining the activity of the compounds of the present invention are described in United States patent number 5,747,498, referred to above.
Administration of the compounds of the present invention (hereinafter the active compound(s)") can be effected by any method that enables delivery of the compounds to he site of action. These methods include oral routes intraduodenal routes, parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular and infusion), topical, and rectal administration. The amount of the active compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration and the judgment of the prescribing physician. However, an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg kg/day, in single or divided doses. For a 70 kg
human, this would amount to about 0.0S to about 7 g/day, preferably about 0.2 to about 2.5 g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effects provided that such larger doses are first divided into several smaller doses by administration throughout the day. The active compound may be applied as a sole therapy or may involve one or more other antitumor substances, for example those selected from, for example, mitotic inhibitors. For example vinblastine; alkylating agents, for example cis-platin, carboplatin and cyclophosphamide; antimetabolites, for example 5-fuorouracil, cytosine arabinoside and hydroxyurea, or, for example, one of the preferred antimetabolites disclosed in European patent Application No. 239362 such as N-(5-[N-(3,4dihydro-2-methyl-4-oxoquinazolin-6- ylmethyl)-N-methyiamino]-2-thenoyl)-L-glutamic acid; growth factor inhibitors; cell cycle inhibitors; intercalating antibiotics, for example adriamycin and bleomycin; enzymes, for examples interferon; and anti-hormones, for example anti-estrogens such as Nolvadex™ (Tamoxifen) or for example anti-androgens such as Casodex™. Such conjoint treatment may be achievable by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.
The pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet capsule, pill, powder, sustained release formulations, solution, suspension for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjutants, etc. Exemplary parenteral administration forms include solutions or suspensions of the active compounds in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired. Suitable pharmaceutical carriers include inert diluents or fillers, water and various organic solvents. The pharmaceutical compositions may, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus for oral administration, tablets containing various excipients, such as citric acid may be employed together with various disintegrant such as starch, alginic acid and certain complex silicates and with binding agents such as sucrose, gelatin and acacia.
Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed in soft and hard filled gelatin capsules. Preferred materials, therefore, include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration the active compound herein may be combined with various sweetening or flavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, ethanoi, propylene glycol, glycerin, or combinations thereof. Methods of preparing various pharmaceutical compositions with a specific amount of active compound are known, or will be apparent to those skilled in this art. For examples, see Reminqton's Pharmaceutical Sciences, Mack Publishing Company, Easter, Pa., 15th Edition (1975). The examples and preparations provided below further illustrate and exemplify the compounds of the present invention and methods of preparing such compounds. It is to be understood that the scope of the present invention is not limited in any way by the scope of the following examples and preparations.
/
Examples
Experimental conditions
X-ray Powder Diffraction:
XRPD patterns were obtained using a T2 high-throughput XRPD set-up by
Avantium technologies, The Netherlands. The plates were mounted on a Bruker GADDS diffractometer equipped with a Hi-Star area detector. The XRPD platform was calibrated using Silver Behenate for the long d-spacings and Corundum for the short d spacings.
Data collection was carried out at room temperature using monochromatic CuK(alpha)radiation (1.54178 A) in the two-theta region between 1.5 °and 41.5 °. The diffraction pattern of each well is collected in two two-theta ranges (1.5 ° < 2Θ < 21.5 ° for the first frame, and 19.5 0 < 2Θ < 41.5 0 for the second) with an exposure time of 120 s for each frame. One of ordinary skill in the art understands that experimental differences may arise due to differences in instrumentation, sample preparation, or other factors. Typically XRPD data are collected with a variance of about 0.3 degrees two-theta, preferable about 0.2 degrees, more preferably 0.1 degrees, even
more preferable 0.05 degrees. This has consequences for when X-ray peaks are considered overlapping.
High-resolution X-ray Powder Diffraction:
The High resolution powder patterns were collected on the D8 Advance system in the Brag-Brentano geometry equipped with LynxEye solid state detector. The radiation used for collecting the data was CuK(alpha1 = 1.54056 A) monochromatized by the Germanium crystal. The patterns were collected in various 28 ranges, starting from about 2 4 °2Θ until about 60-65 °28, with a step in the ragne of 0.04-0.16 °2Θ without further processing. AH patterns were taken at Room Temperature, approximately 295K.
Single-crystal X-ray diffraction
Suitable single crystals were selected and glued to a glass fibre, which was then mounted on an X-ray diffraction goniometer. X-ray diffraction data were collected for these crystals at a temperature of 120K and at room temperature, using a KappaCCD system and MoKO radiation, generated by a FR590 X-ray generator (Bruker Nonius, Delft, The Netherlands).
Unit-cell parameters and crystal structures were determined and refined using the software package aXus.
Thermal analysis:
Melting properties were obtained from DSC thermograms, recorded with a heat flux DSC822e instrument (Mettler-Toledo GmbH, Switzerland). The DSC822e was calibrated for temperature and enthalpy with a small piece of indium (m.p. = 156.6°C; delta-H(f) = 28.45 J/g). Samples were sealed in standard 40 microliter aluminum pans and heated in the DSC from 25°C to 300eC, at a heating rate of 20°C/min. Dry N2 gas, at a flow rate of 50 ml/min, was used to purge the DSC equipment during measurement.
Mass loss due to solvent or water loss from the crystals was determined by TGA SDTA. Monitoring of the sample weight, during heating in a TGA SDTA851e instrument (Mettler-Toledo GmbH, Switzerland), resulted in a weight vs. temperature curve. The TGA SDTA851e was calibrated for temperature with indium and aluminium.
Samples were weighed into 100 microliter aluminium crucibles and sealed. The seals were pin-holed and the crucibles heated in the TGA from 25°C to 300°C at a heating rate of 20°C/min. Dry N2 gas is used for purging. Melting point determinations based on DSC have a variability of +/- 2.0 degrees Celsius, preferably 1.0 degrees Celsius.
Raman spectroscopy:
The Raman spectra were collected with a Raman microscope mW (Kaiser Opticals Inc) at 0.96 cm-1 resolution using a laser of 780 nm and a power output of 100. Eriotinib free base
Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art. Dry solid was analyzed by XRPD and additional analytical methods. Analytical data are presented in Figures 19A - 19D.
Example 1
Preparation of Eriotinib ethanesulfonate polymorph ERET ULT-1
Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 1 g of Eriotinib free base was weighted in a 50 mL glass reactor in the Mettler Toledo MultiMaxMT device equipped with mechanical stirring. Ethylacetate was added to a final concentration of approximately 50 mg/mL of Eriotinib free base. Ethanesuifonic acid was added drop wise in a ratio of 1.1 with respect to the free base of Eriotinib to the above reaction mass under stirring with a speed of 200 rpm. The reactor was heated from rT to 60°C with a rate of 1°C/min and kept at 60°C for 60 minutes. Subsequently reactor was allowed to cool to 5°C at rate of 1 °C hr and kept at 5°C for 35- 38 hr. Stirring speed during the temperature profile was 300 rpm. Solid material was obtained by filtration under vacuum with a 5 μηι filter. The solids were dried at 20 -25 °C at 200 mbar for approximately 1 day and additionally at 40°C and 200 mbar for about 4 -
5 h. Dry solid was analyzed by XRPD and additional analytical methods. Analytical data are presented in Figures 1 A - 1 E.
Example 2
Preparation of Erlotinib ethanesulfonate polymorph ERET ULT-2
Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical
Group. The free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 1 g of Erlotinib free base was weighted in a 50 mL glass reactor in the Mettler Toledo MultiMax T device equipped with mechanical stirring. Water was added to a final concentration of approximately 50 mg/mL of Erlotinib free base. Ethanesulfonic acid was added drop wise in a ratio of 1.1 with respect to the free base of Erlotinib to the above reaction mass under stirring with a speed of 200 rpm. The reactor was heated from rT to 60°C with a rate of TC/min and kept at 60°C for 60 minutes. Subsequently reactor was allowed to cool to 5°C at rate of 1°C hr and kept at 5°C for 35-38 hr. Stirring speed during the temperature profile was 300 rpm. Solid material was obtained by evaporation. The solids were dried at 20 -25 °C at 200 mbar for approximately 1 day and additionally at 40°C and 200 mbar for about 4 - 5 h. Dry solid was analyzed by XRPD and additional analytical methods. Analytical data are presented in Figures 2A - 2E.
Example 3
Preparation of Erlotinib isethionate polymorph ERIS ULT-1
Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 1 g of Erlotinib free base was weighted in a 50 mL glass reactor in the Mettler Toledo ultiMax"7 device equipped with mechanical stirring. To the free base 2- hydroxy-ethanesulfonic acid (isethionic acid) was added in a ratio of 1.1 with respect to the free base of Erlotinib. Subsequently, ethylacetate was added to a final concentration of approximately 50 mg/mL of Erlotinib free base. The reactor was heated from rT to 60°C with a rate of 1 °C/min and kept at 60°C for 60 minutes. Subsequently the reactor was allowed to cool to 5°C at rate of 1"C hr and kept at 5°C for 35-38 hr. Stirring speed during the temperature profile was 300 rpm. Solid material was obtained by filtration
under vacuum with a 5 μηι filter. The solids were dried at 20 -25 °C at 200 mbar for approximately 1 day and additionally at 40°C and 200 mbar for about 4 - 5 h. Subsequently, the solids were dispensed in water and the resulting slurry was stirred at room temperature for at least 1 day and up till 5 days. Solid material was separated from water, dried as mentioned above and analyzed by XRPD and additional analytical methods. Analytical data are presented in Figures 3A - 3F.
Example 4
Preparation of Erlotinib isethionate polymorph ERIS ULT-2
Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 40 mg of Erlotinib free base was solid dosed in a 1.8 ml_ glass vial. To the free base 2-hydroxy-ethanesulfonic acid (isethionic acid) was added in a ratio of 1.1 with respect to the free base of Erlotinib. Subsequently, ethylacetate was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL) of Erlotinib free base. The vials were sealed and heated from rT to 60eC with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5°C at rate of 1°C/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor and dried at 20 -25 °C at 200 mbar for at least 1 day and up till 6 days. If remaining solid was still wet further drying was done at 20-25 °C at 5 mbar until sample was completely dry as judged by visual inspection. Dry solid was analyzed by XRPD and TGA(MS). Analytical data are presented in Figures 4A -4C.
Example 5
Preparation of Erlotinib isethionate polymorph ERIS ULT-3
Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical
Group. The free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 40 mg of Erlotinib free base was solid dosed in a 1.8 mL glass vial. To the free base 2-hydroxy-ethanesulfonic acid (isethionic acid) was added in a ratio of 1.2 with respect to the free base of Erlotinib. Subsequently, methylacetate was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL) of Erlotinib free
base. The vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5"C at rate of c/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor and dried at 20 -25 °C at 200 mbar for at least 1 day and up till 6 days. If remaining solid was still wet further drying was done at 20-25 °C at 5 mbar until sample was completely dry as judged by visual inspection, Dry solid was analyzed by XRPD and TGA(MS). Analytical data are presented in Figures 5A - 5C.
Example 6
Preparation of Erlotinib isethionate polymorph ERIS ULT-4
Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical
Group. The free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 40 mg of Erlotinib free base was solid dosed in a 1.8 mL glass vial. To the free base 2-hydroxy-ethanesulfonic acid (isethionic acid) was added in a ratio of 1.2 with respect to the free base of Erlotinib. Subsequently, methylacetate was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL) of Erlotinib free base. The vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5°C at rate of 1 °C/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor and dried at 20 -25 °C at 200 mbar for at least 1 day and up till 6 days. If remaining solid was still wet further drying was done at 20-25 °C at 5 mbar until sample was completely dry as judged by visual inspection. Subsequently, the solids were dispensed in water and the resulting slurry was stirred at room temperature for at least 1 day and up till 5 days. Solid material was separated from water, dried and analyzed by XRPD (Figure 6).
Example 7
Preparation of Erlotinib bromide polymorph ERBR ULT-1
Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 1 g of Erlotinib free base was weighted in a 50 mL glass reactor in the Mettler Toledo MultiMax T device equipped with mechanical stirring. Ethylacetate was added to a final concentration of approximately 50 mg/mL of Erlotinib free base. 48 % of hydrobromic acid in ACS reagent was added drop wise in a ratio of 1.1 with respect to the free base of Erlotinib to the above reaction mass under stirring with a speed of 200 rpm. The reactor was heated from rT to 60°C with a rate of 10C/min and kept at 60X for 60 minutes. Subsequently the reactor was allowed to cool to 5°C at rate of rc/hr and kept at 5°C for 35-38 hr. Stirring speed during the temperature profile was 300 rpm. Solid material was obtained by filtration under vacuum with a 5 μηι filter. The solids were dried at ,20 -25 °C at 200 mbar for approximately 1 day and additionally at 40°C and 200 mbar for about 4 - 5 h. Dry solid was analyzed by XRPD and additional analytical methods. Analytical data are presented in Figures 7A - 7F.
Example 8
Preparation of Erlotinib bromide polymorph ERBR ULT-2
Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical
Group. The free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 40 mg of Erlotinib free base was solid dosed in a 1.8 mL glass vial. To the free base 48 % hydrobromic acid In ACS reagent was added together with acetone/water 50:50 in a ratio of 1.1 - 1.2 with respect to the free base of Erlotinib. The final concentration of Erlotinib free base in the solvent was approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL). The vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5°C at rate of 1 °C/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor and dried at 20 -25 °C at 200 mbar for at least 1 day and up till 6 days. If remaining solid was still wet further drying was done at 20-25 °C at 5 mbar until sample was completely dry as judged by visual inspection. Dry solid was analyzed by XRPD (Figure 8).
Example 9
Preparation of Erlotinib bromide polymorph ERBR ULT-3
Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 40 mg of Eriotinib free base was solid dosed in a 1.8 mL glass vial. To the free base 48 % hydrobromic acid in ACS reagent was added together with methanol water 50:50 in a ratio of 1.1 with respect to the free base of Eriotinib. The final concentration of Eriotinib free base in the solvent was approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL). The vials were sealed and heated from rT to 60eC with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5°C at rate of 1 "C/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor and dried at 20 -25 °C at 200 mbar for at least 1 day and up till 6 days. If remaining solid was still wet further drying was done at 20-25 °C at 5 mbar until sample was completely dry as judged by visual inspection. Dry solid was analyzed by XRPD (Figure 9A).
Example 10
Preparation of Eriotinib bromide polymorph ERBR ULT-4
Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 40 mg of Eriotinib free base was solid dosed in a 1.8 mL glass vial. To the free base 48 % hydrobromic acid in ACS reagent was added together with methanol in a ratio of 1.1 with respect to the free base of Eriotinib. The final concentration of Eriotinib free base in methanol was approximately 50 mg mL (range of 48.8 - 52.9 mg/mL). The vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5°C at rate of 1°C/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor. The solvent from the mother liquor was evaporated and the remaining solid was dried and analyzed by XRPD (Figure 10). Drying was carried out at 20 -25 °C at 200 mbar for at least 1 day and up till 6 days. If remaining solid was still wet further drying was done at 20-25 °C at 5 mbar until sample was completely dry as judged by visual inspection.
Example 11
Preparation of Eriotinib bromide polymorph ERBR ULT-5
Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 40 mg of Eriotinib free base was solid dosed in a 1.8 mL glass vial. To the free base 48 % hydrobromic acid in ACS reagent was added together with methanol in a ratio of 1.1 with respect to the free base of Eriotinib. The final concentration of Eriotinib free base in methanol was approximately 50 mg/mL (range of 48.8 - 52.9 mg mL). The vials were sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5eC at rate of 1°C/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor. The solvent from the mother liquor was evaporated and the remaining solid was dried at 20 -25 °C at 200 mbar for at least 1 day and up till 6 days. If remaining solid was still wet further drying was done at 20-25 °C at 5 mbar until sample was completely dry as judged by visual inspection. Subsequently, the solids were exposed to 40°C and 75% relative humidity for 48 h and re-analyzed by XRPD (Figure 11).
Example 12
Preparation of Eriotinib malonate polymorph ERMO ULT-1
Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 1 g of Eriotinib free base was weighted in a 50 mL glass reactor in the Mettler Toledo Multi axMT device equipped with mechanical stirring. To the free base malonic acid was added in a ratio of 1.1 with respect to the free base of Eriotinib. Subsequently, ethanol/water 50:50 was added to a final concentration of approximately 50 mg/mL of Eriotinib free base. The reactor was heated from rT to 60°C with a rate of c/min and kept at 60°C for 60 minutes. Subsequently the reactor was allowed to cool to 5°C at rate of TC/hr and kept at 5°C for 35-38 hr. Stirring speed during the temperature profile was 300 rpm. Solid material was obtained by filtration under vacuum with a 5 μηι filter. The solids were dried at 20 -25 °C at 200 mbar for approximately 1 day and additionally at 40°C and 200 mbar for about 4 - 5 h. Subsequently, the solids were dispensed in water and the resulting slurry was stirred at room temperature for at least 1 day and up till 5 days. Solid material was separated from water, dried as mentioned
above and analyzed by XRPD and additional analytical methods. Analytical data are presented in Figures 12A - 12F.
Example 13
Preparation of Eriotinib malonate polymorph ERMO ULT-2
Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 40 mg of Eriotinib free base was solid dosed in a 1.8 mL glass vial. To the free base malonic acid was added in a ratio of 1.1 with respect to the free base of Eriotinib Subsequently, methanol/water 50:50 was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL) of Eriotinib free base. The vial was sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently the vial was allowed to cool to 5°C at rate of 1°C/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor. The solvent from the mother liquor was evaporated and the remaining solid was dried and analyzed by XRPD. Drying was carried out at 20 -25 °C at 200 mbar for at least 1 day and up till 6 days. If remaining solid was still wet further drying was done at 20-25 °C at 5 mbar until sample was completely dry as judged by visual inspection. The XRPD pattern is presented in Figure 13.
Example 14
Preparation of Eriotinib L-lactate polymorph ERLA ULT-1
Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 40 mg of Eriotinib free base was solid dosed in a 1.8 mL glass vial. To the free base Lactic acid was added in a ratio of 1.2 with respect to the free base of Eriotinib Subsequently, methylacetate was added to a final concentration of approximately 50 mg mL (range of 48.8 - 52.9 mg/mL) of Eriotinib free base. The vial was sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vials were allowed to cool to 5°C at rate of 1°C/hr and kept at 5°C for 35-
38 hr. Solid material was separated from the mother liquor and dried at 20 -25 °C at 200 mbar for at least 1 day and up till 6 days. If remaining solid was still wet further drying was done at 20-25 °C at 5 mbar until sample was completely dry as judged by visual inspection. The XRPD pattern is presented in Figure 14.
Example 15
Preparation of Eriotinib succinate polymorph ERSC ULT-1
Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 1 g of Eriotinib free base was weighted in a 50 mL glass reactor in the ettler Toledo ultiMax T device equipped with mechanical stirring. To the free base succinic acid was added in a ratio of 1.1 with respect to the free base of Eriotinib. Subsequently, ethanol/water 50:50 was added to a final concentration of approximately 50 mg/mL of Eriotinib free base. The reactor was heated from rT to 60°C with a rate of 1°C/min and kept at 60°C for 60 minutes. Subsequently the reactor was allowed to cool to 5°C at rate of 1°C/hr and kept at 5"C for 35-38 hr. Stirring speed during the temperature profile was 300 rpm. Solid material was obtained by filtration under vacuum with θ δ τη filter. The solids were dried at 20 -25 °C at 200 mbar for approximately 1 day and additionally at 40°C and 200 mbar for about 4 - 5 h. Dry solid was analyzed by XRPD and additional analytical methods. Analytical data are presented in Figures 15A - 15F.
Example 16
Preparation of Eriotinib succinate polymorph ERSC ULT-2
Eriotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Eriotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 50 mg of Eriotinib free base was solid dosed in a stainless steel vial. To the free base succinic acid was added in a ratio of 1.1 with respect to the free base of Eriotinib. Subsequently, about 5μΙ- of water was added and the vial was sealed and
shaken for at least 20 minutes and up till 90 minutes at a frequency of 30 s"\ Solid material was analyzed by XRPD (Figure 16).
Example 17
Preparation of Erlotinib succinate polymorph ERSC ULT-3
Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical
Group. The free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 40 mg of Erlotinib free base was solid dosed in a 1.8 mL glass vial. To the free base succinic acid was added in a ratio of 1.1 with respect to the free base of Erlotinib. Subsequently, ethanol was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg/mL) of Erlotinib free base. The vial was sealed and heated from rT to 60°C with a rate of 10eC/min and kept at 60X for 60 minutes. Subsequently vial was allowed to cool to 5°C at rate of 1°C/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor and dried at 20 -25 °C at 200 mbar for at least 1 day and up till 6 days. If remaining solid was still wet further drying was done at 20-25 °C at 5 mbar until sample was completely dry as judged by visual inspection. The XRPD pattern is presented in Figure 17.
Example 18
Preparation of Erlotinib succinate polymorph ERSC ULT-4
Erlotinib hydrochloride salt was obtained from Jinan Sky-worth Pharmaceutical Group. The free base of Erlotinib was obtained from the hydrochloride salt by standard conversion known to a person skilled in the art.
About 40 mg of Erlotinib free base was solid dosed in a 1.8 mL glass vial. To the free base succinic acid was added in a ratio of 1.1 with respect to the free base of Erlotinib. Subsequently, 1 ,2-dimethoxyethane was added to a final concentration of approximately 50 mg/mL (range of 48.8 - 52.9 mg mL) of Erlotinib free base. The vial was sealed and heated from rT to 60°C with a rate of 10°C/min and kept at 60°C for 60 minutes. Subsequently vial was allowed to cool to 5°C at rate of TC/hr and kept at 5°C for 35-38 hr. Solid material was separated from the mother liquor and dried at 20 -25 °C at 200 mbar for at least 1 day and up till 6 days. If remaining solid was still wet further
drying was done at 20-25 °C at 5 mbar until sample was completely dry as judged by visual inspection. The XRPD pattern is presented in Figure 18.
Example 19
Comparative pharmacokinetic study of erlotinib solid forms and erlotinib mesylate salt
Batches of the solid forms of erlotinib and erlotinib mesylate salt are prepared with comparable crystal size by sieving through a [mu]M sieve. Small cellulose capsules are filled with approximately 15 mg of the solid forms . Twelve Male wistar rats of approximately 300 grams each are dosed one capsule by oral gavage followed by 1 mL of tap water. At regular intervals a small quantity of blood is sampled from each rat by a tail vein puncture. Blood samples are immediately frozen in Liquid N2 for further processing. After all samples are collected, plasma preparations are made of each sample. The plasma samples are further worked up for analysis by LC-MS-MS for their content of erlotinib. Efficiency of extraction is determined by comparison by spiking rat plasma samples with known amounts of erlotinib. The concentration of erlotinib is quantified in each sample by means of LC-MS-MS against a calibration curve. The results of the comparative pharmacokinetic are presented. From the PK data bioequivalency of the erlotinib sold forms to the mesylate and/or chloride salt of erlotinib can be determined.
Example 20
Study of the food effect of erlotinib solid forms
The effects of food on the pharmacokinetics of erlotinib are investigated. In a single-dose study 150 mg of erlotinib, either the mesylate salt, the hydrochloride salt or the solid forms described herein are administered under either fasting or fed conditions. The area under the plasma concentration-time curve is determined by the geometric mean ratio (GMR) observed under fed or fasted conditions. In another study, identical doses of erlotinib, either the mesylate salt, the hydrochloride salt or the solid forms described herein are administered daily for 8 days, either 7 days of fasting followed by feeding on day 8, or the reverse sequence. The plasma concentration-time curve is determined to determine the food effect of the various erlotinib forms. These studies provide an indication that the solid forms described herein can play a role in controlling
the fact that food can substantially increase plasma exposure to eriotinib. As the clinical practice allows only for a maximum tolerated dose of eriotinib, the use of other forms of eriotinib may lower the food effect of eriotinib resulting in that eriotinib may be taken also under conditions of fed or reduced fasting thereby alleviating discomfort for patients.
Claims
1. Salt of Ertotinib, wherein the salt is selected from the group consisting of ethanesulfonate, isethionate, bromide, malonate, L-lactate, succinate.
2. Salt of Eriotinib according to claim 1 , wherein the salt is the ethanesulfonate salt.
3. Salt of Eriotinib according to claim 1 , wherein the salt is the isethionate salt.
4. Salt of Eriotinib according to claim 1 , wherein the salt is the bromide salt.
5. Salt of Eriotinib according to claim 1 , wherein the salt is the malonate salt.
6. Salt of Eriotinib according to claim 1 , wherein the salt is the L-lactate salt.
7. Salt of Eriotinib according to claim 1 , wherein the salt is the succinate salt.
8. Salt of Eriotinib ETHANESULFONATE according to claim 2, wherein the salt is the Form ERET ULT-1 , characterized by one, two, three, four, five, six, seven or eight peaks selected from the group consisting of 5.42, 6.94, 8.65, 10.78, 13.16, 16.17, 18.94, 20.62, 21.76, 23.82, 25.32 (2Θ) +/- 0.3.
9. Salt of Eriotinib ETHANESULFONATE according to claim 2, wherein the salt is the Form ERET ULT2, characterized by one, two, three, four, five, six, seven or eight peaks selected from the group consisting of 5.9, 8.36, 10.18, 11.73, 13.02, 13.27, 16.8, 16.89, 17.09, 17.88, 18.81 , 19.57, 19.87, 20.05, 20.44, 20.72, 21.57, 22.21 , 23.62, 23.98, 24.72, 25.16, 25.38, 25.72, 26.01, 26.29, 26.73, 27.84, 28.15, 28.93, 29.56, 30.06, 30.49, 31.09. 31.72, 32.77, 33.94, 34.22, 34.62, 36.38 (2Θ) +/- 0.3.
10. Salt of Eriotinib isethionate according to claim 3, wherein the salt is the Form ERIS ULT-1 , characterized by one, two, three, four, five, six, seven or eight peaks selected from the group consisting of 7.31 , 7.43, 7.65, 8.3, 11.37, 11.8, 12.61 , 14.81 , 15.06, 15.91, 16.09, 16.4, 16.66, 20.26, 20.58, 20.92, 21.84, 22.06, 22.24, 22.6, 22.8, 23.11 , 23.37, 23.72, 24.47, 24.9, 25.78, 26.27, 27.11 , 27.65, 28.55. 29.09, 29.58, 30.41 , 30.94 (2Θ) +/- 0.3.
11. Salt of Eriotinib isethionate according to claim 3, wherein the salt is the Form ERIS ULT2, characterized by one, two, three, four, five, six, seven or eight peaks selected from the group consisting of 5.7, 8.18, 12.26, 13.14, 16.34, 17.14, 17.7, 18.54, 19.1 , 20.62, 21.39, 23.04, 24.58, 26.5, 29.15, 30.2, 31.26 (2Θ) +/- 0.3.
12. Salt of Eriotinib isethionate according to claim 3, wherein the salt is the Form ERIS ULT3, characterized by one, two, three, four, five, six, seven or eight peaks selected from the group consisting of 5.38, 6.54, 7.3, 13.38, 14.48, 15.63, 17.86, 9.18, 19.58, 20.54, 21.35 (2Θ) +/- 0.3.
13. Salt of Eriotinib isethionate according to claim 3, wherein the salt is the Form ERIS ULT4, characterized by one, two, three, four, five, six, seven or eight peaks selected from the group consisting of 5.22, 6.38, 7.08, 10.43, 17.26, 18.16, 19.17, 20.42, 22.18, 24.62, 27.45 (2Θ) +/- 0.3.
14. Salt of Eriotinib bromide according to claim 4, wherein the salt is the Form ERBR ULT-1 , characterized by one, two, three, four, five, six, seven or eight peaks selected from the group consisting of 6.23, 7.84, 9.55, 11.39, 12.47, 13.37, 14.76, 15.67, 16.95, 17.63, 20.19, 20.67, 20.93, 21.11 , 21.85, 22.43, 22.96, 23.83, 23.94, 24.43, 24.65, 25.12, 25.90, 26.50, 26.75, 26.95, 28.60, 28.95, 29.70, 32.66, 34.72, 40.08 (2Θ) +/- 0.3.
15. Salt of Eriotinib bromide according to claim 4, wherein the salt is the Form ERBR ULT2, characterized by one, two, three, four, five, six, seven or eight peaks selected from the group consisting of 5.66, 9.58, 12.74, 15.18, 16.99, 13.58, 18.7, 19.1. 20.42, 22.42, 23.38, 23.86, 24.54, 25.18, 25.62, 26.44, 27.29, 28.5. 29.22. 30.58, 31.06, 32.17, 37.57 (2Θ) +/- 0.3.
16. Salt of Eriotinib bromide according to claim 4, wherein the salt is the Form ERBR ULT3, characterized by one, two, three, four, five, six, seven or eight peaks selected from the group consisting of 6.26, 7.78, 9.3, 13.33, 15.5, 16.74, 18.17, 18.66, 19.7, 20.5, 21 , 22.06, 22.94, 23.9, 24.34, 24.98, 26.34, 28.26, 28.87, 29.37, 30.49, 30.99, 32.04, 33.29, 34.1, 35.09, 36.77, 38.14, 40.15 (2Θ) +/- 0.3.
17. Salt of Eriotinib bromide according to claim 4, wherein the salt is the Form ERBR ULT4, characterized by one, two, three, four, five, six, seven or eight peaks selected from the group consisting of 5.9, 8.14, 11.3, 11.66, 12.68, 16.31 , 17.9, 18.87, 21.1 , 22.63, 23.34, 23.82, 25.98, 27.14, 28.42, 29.17, 31.84 (2Θ) +/- 0.3.
18. Salt of Eriotinib bromide according to claim 4, wherein the salt is the Form ERBR ULT5, characterized by one, two, three, four, five, six, seven or eight peaks selected from the group consisting of 6.22, 8.38, 11.78, 14.68, 16.85, 18.14, 18.7,
19.44, 20.36, 20.92, 22.63, 23.13, 24.62, 25.25, 26.46, 27.82, 28.59, 29.46 (2Θ) +/- 0.3.
19. Salt of Eriotinib malonate according to claim 5, wherein the salt is the Form ERMO ULT-1 , characterized by one, two, three, four, five, six, seven or eight peaks selected from the group consisting of 6.68, 8.85, 9.31 , 12.07, 13.29, 15.98,
16.78, 17.43, 18.91, 19.36, 20.17, 20.44, 21.05, 21.67, 22.85, 23.09, 23.70, 24.70, 24.89, 26.68, 26.90, 27.69, 28.25, (2Θ) +/- 0.3.
20. Salt of Eriotinib malonate according to claim 5, wherein the salt is the Form ERMO ULT2, characterized by one, two, three, four, five, six, seven or eight peaks selected from the group consisting of 2.26, 5.42, 8.26, 10.82, 14.3, 16.5,
17.86, 20.81, 21.74, 22.46, 24.06, 25.14, 25.78, (2Θ) +/- 0.3.
21. Salt of Eriotinib L-lactate according to claim 6, wherein the salt is the Form ER ULTY, characterized by one, two, three, four, five, six, seven or eight peaks selected from the group consisting of 6.46, 7.83, 12.41 , 12.81 , 15.84, 16.66, 18.2, 19.48, 20.42, 21.03, 21.7, 22.58, 23.53, 24.64, 26.24, 25.66, 26.75, 27.2, 29.24,
(2Θ) +/- 0.3.
22. Salt of Eriotinib succinate according to claim 7, wherein the salt is the Form ERSC ULT-1, characterized by one, two, three, four, five, six, seven or eight peaks selected from the group consisting of 7.34, 7.45, 8.04, 11.64, 12.05, 14.40, 14.71, 14.95, 15.15, 15.90, 16.35, 16.54, 19.91 , 20.38, 20.84, 21.27, 21.50,
21.77, 22.15, 22.51 , 22.69, 22.87, 23.27, 23.94, 24.26, 25.26, 25.67, 26.70, 27.51, 28.46, 29.08, (2Θ) +/- 0.3.
23. Salt of Eriotinib succinate according to claim 7, wherein the salt is the Form ERSC ULT2, characterized by one, two, three, four, five, six, seven or eight peaks selected from the group consisting of 6.54, 7.34, 9.82, 11.36, 12.88, 14.77,
18.74, 19.67, 20.46, 22.17, 22.78, 23.94, 25.18, 26.3, 27.02, 27.58, 28.62, 29.3, 31.29, (28) +/- 0.3.
24. Salt of Eriotinib succinate according to daim 7, wherein the salt is the Form ERSC ULT3, characterized by one, two, three, four, five, six, seven or eight peaks selected from the group consisting of 6.62, 7.97, 13.04, 15.2, 16.31 , 17.71 ,
19.21, 19.91 , 21.07, 21.73, 22.63, 24.49, 25.49, 26.34, 27.45, 28.95, 30.31, (2Θ) +/- 0.3.
25. Salt of Eriotinib succinate according to claim 7, wherein the salt is the Form ERSC ULT4, characterized by one, two, three, four, five, six, seven or eight peaks selected from the group consisting of 3.7, 6.66, 7.46, 8.28, 13.05, 13.66, 14.54, 15.12, 18.5, 19.55, 20 33, 22 15, 22.61, 24.63, 25.29, 25.82, 26 52, 29.38, 31.36, (2θ) +/- 0.3.
26. Method for the preparation of Eriotinib salts and solid forms as defined in claims 1-25, comprising the steps of
combining eriotinib free base with about 1.1 - 1.2 equivalent of acid; adding solvent to a concentration of about 50 mg/ml;
- warming the mixture to about 60 degrees Celsius at a rate of about 1-10 degrees/minute;
keeping the mixture at about 60 degrees Celsius for a period between about 30-90 minutes;
allowing the mixture to cool to about 5 degrees Celsius at a rate of about 1-10 degrees/minute;
keeping the mixture for about 0-50 hours;
optionally evaporating the liquid;
isolating the solid;
drying the solid, optionally at reduced pressure;
wherein the acids and solvents are:
dimethoxyethane, 1 ,4-dioxane, 3- methyl-1-butanol, ethanol, ethylacetate, water, acetone/water, 2,2,2- trifluoroethanol, tert-butyi methyl ether, ethanol/water, methanol/water malonate malonic acid methylacetate, acetonitrile,
ethanol/water, methanol/water, tetrahydrofuran/water, acetonitrile water, methanol, acetone/water, 1,4-dioxane
L-lactate Lactic acid methylacetate, 1,2-dimethoxyethane, 3- methyl-1-butanol, ethanol, ethylacetate succinate succinic acid 2,2,2-trifluoroethanol, ethylacetate, water, ethanol/water, methanol/water, acetone/water, acetonitrile/water, tetrahydrofuran/water, methylacetate, methanol, tetrahydrofuran, acetonitrile, 1 ,4-dioxane, 3-methyl-1-butanol, ethanol, tert-butyl methyl ether
27. Pharmaceutical composition comprising any of the eriotinib salts of claims 1-25
together with a pharmaceutically acceptable carrier.
28. Use of a pharmaceuttcal composition comprising any of the eriotinib salts of
claims 1-25 as a medicament.
29. Use of any of the eriotinib salts of claims 1-25 in the preparation of a medicament
for.
the treatment of pancreatitis or kidney disease (including proliferative glomerulonephritis and diabetes-induced renal disease) in a mammal, including a human;
the treatment of hyperproliferative disorder, specifically non-small cell lung cancer and bronchioalveolar cancer, in a mammal, including a human;
the prevention of blastocyte implantation in a mammal, including a human;
the treatment of a disease related to vasculogenesis or angiogenesis in a mammal, including a human;
the treatment of a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, skin diseases such as psoriasis, eczema, and scleroderma, diabetes, diabetes retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer in a mammal, including a human;
- the treatment of cancer selected from the group consisting of brain, lung, squamous cell, bladder, gastric, pancreatic, breast, neck, head, renal (kidney), ovarian, prostate, colorectal, oesophageal, gynaecological or thyroid cancer in a mammal, including a human;
the treatment of non-cancerous hyperproliferative disorder selected from the group consisting of benign hyperplasia of the skin (psoriasis) or prostate
(benign prostatic hypertrophy (BPH));
the treatment of psoriasis, BPH, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, gynaecologic tumors (uterine sarcomas, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina or carcinoma of the vulva), Hodgkin's disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system (cancer of the thyroid, parathyroid or adrenal glands), sarcomas of soft tissues, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, solid tumors of childhood, lymphatic lymphomas, cancer of the bladder, cancer of the kidney or urethra (renal call carcinoma, carcinoma of the renal pelvis), or neoplasms of the central nervous system (primary CNS lymphoma, spinal axis tumors, brainstem gliomas or pituitary adenomas.
30. Use of any of the erlotinib salts and solid forms of claims 1-25 in:
the treatment of pancreatitis or kidney disease (including proliferative glomerulonephritis and diabetes-induced renal disease) in a mammal, including a human;
the treatment of hyperproliferative disorder, specifically non-small cell lung cancer and bronchioalveolar cancer, in a mammal, including a human;
the prevention of blastocyte implantation in a mammal, including a human;
the treatment of a disease related to vascuiogenesis or angiogenesis in a mammal, including a human;
the treatment of a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, skin diseases such as psoriasis, eczema, and scleroderma, diabetes, diabetes retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer in a mammal, including a human;
the treatment of cancer selected from the group consisting of brain, lung, squamous cell, bladder, gastric, pancreatic, breast, neck, head, renal (kidney), ovarian, prostate, colorectal, oesophageal, gynaecological or thyroid cancer in a mammal, including a human;
the treatment of non-cancerous hyperproliferative disorder selected from the group consisting of benign hyperplasia of the skin (psoriasis) or prostate (benign prostatic hypertrophy (BPH));
the treatment of psoriasis, BPH, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, gynaecologic tumors (uterine sarcomas, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina or carcinoma of the vulva), Hodgkin's disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system (cancer of the thyroid, parathyroid or adrenal glands), sarcomas of soft tissues, cancer of the urethra, cancer of the penis, prostate cancer, chronic or
acute leukemia, solid tumors of childhood, lymphatic lymphomas, cancer of the bladder, cancer of the kidney or urethra (renal call carcinoma, carcinoma of the renal pelvis), or neoplasms of the central nervous system (primary CNS lymphoma, spinal axis tumors, brainstem gliomas or pituitary adenomas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26588809P | 2009-12-02 | 2009-12-02 | |
US61/265,888 | 2009-12-02 | ||
US26628209P | 2009-12-03 | 2009-12-03 | |
US61/266,282 | 2009-12-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011068403A2 true WO2011068403A2 (en) | 2011-06-09 |
WO2011068403A3 WO2011068403A3 (en) | 2011-09-15 |
Family
ID=43533387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2010/050809 WO2011068403A2 (en) | 2009-12-02 | 2010-12-02 | Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011068403A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102584719A (en) * | 2012-02-02 | 2012-07-18 | 瑞阳制药有限公司 | Preparing technology of erlotinib hydrochloride |
WO2013054147A2 (en) | 2011-10-10 | 2013-04-18 | Egis Gyógyszergyár Nyilvánosan Műkődő | Erlotinib salts |
WO2014118737A1 (en) | 2013-01-31 | 2014-08-07 | Ranbaxy Laboratories Limited | Erlotinib salts |
CN113880897A (en) * | 2020-10-30 | 2022-01-04 | 杭州拉林智能科技有限公司 | Flavonoid glycoside-organic amine tyrosine kinase inhibitor double-salt compound and preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0239362A2 (en) | 1986-03-27 | 1987-09-30 | Imperial Chemical Industries Plc | Anti-tumor agents |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US20020006443A1 (en) | 1999-12-23 | 2002-01-17 | Curatolo William J. | Pharmaceutical compositions providing enhanced drug concentrations |
US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101441930B1 (en) * | 2007-04-04 | 2014-09-19 | 시플라 리미티드 | Process for preparation of erlotinib and its pharmaceutically acceptable salts |
-
2010
- 2010-12-02 WO PCT/NL2010/050809 patent/WO2011068403A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0239362A2 (en) | 1986-03-27 | 1987-09-30 | Imperial Chemical Industries Plc | Anti-tumor agents |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
US20020006443A1 (en) | 1999-12-23 | 2002-01-17 | Curatolo William J. | Pharmaceutical compositions providing enhanced drug concentrations |
Non-Patent Citations (1)
Title |
---|
"Reminqton's Pharmaceutical Sciences", 1975, MACK PUBLISHING COMPANY |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013054147A2 (en) | 2011-10-10 | 2013-04-18 | Egis Gyógyszergyár Nyilvánosan Műkődő | Erlotinib salts |
WO2013054147A3 (en) * | 2011-10-10 | 2013-06-13 | Egis Gyógyszergyár Nyilvánosan Műkődő | Erlotinib salts |
CN103958483A (en) * | 2011-10-10 | 2014-07-30 | 埃吉斯药物私人有限公司 | Erlotinib salts |
CN102584719A (en) * | 2012-02-02 | 2012-07-18 | 瑞阳制药有限公司 | Preparing technology of erlotinib hydrochloride |
WO2014118737A1 (en) | 2013-01-31 | 2014-08-07 | Ranbaxy Laboratories Limited | Erlotinib salts |
CN113880897A (en) * | 2020-10-30 | 2022-01-04 | 杭州拉林智能科技有限公司 | Flavonoid glycoside-organic amine tyrosine kinase inhibitor double-salt compound and preparation method and application thereof |
WO2022089590A1 (en) * | 2020-10-30 | 2022-05-05 | 杭州拉林智能科技有限公司 | Complex salt compound of flavonoid glycoside-organic amine tyrosine kinase inhibitor, preparation method therefor and use thereof |
CN113880897B (en) * | 2020-10-30 | 2023-06-02 | 杭州拉林智能科技有限公司 | Flavonoid glycoside-organic amine tyrosine kinase inhibitor double salt compound and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2011068403A3 (en) | 2011-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP1252A (en) | N-[3-ethynylphenylamino]-6.7-bis9-Methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate. | |
NO330781B1 (en) | Polymorphic forms of {6,7-Bis (2-methoxyethoxy) quinazolin-4-yl (3-ethynylphenyl) amine hydrochloride, process for the preparation of such, pharmaceutical compositions comprising such, such compounds for use as a medicament, and such compounds for the treatment of diseases | |
EP3428159B1 (en) | Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof | |
US8372856B2 (en) | Hydrates of erlotinib hydrochloride | |
CA3016826A1 (en) | Salt of pyridinyl amino pyrimidine derivative, preparation method therefor, and application thereof | |
CN105294717B (en) | A kind of salt of EGFR inhibitor, crystal formation and application thereof | |
WO2011068403A2 (en) | Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts | |
WO2019218987A1 (en) | Egfr inhibitors | |
US8722884B2 (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
US20100004449A1 (en) | Crystalline forms of erlotinib base and erlotinib hcl | |
US7521456B2 (en) | N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate | |
WO2008098485A1 (en) | The salts of 4-aniline quinazoline derivative | |
CN103864680B (en) | There is the 7-chloro-4-oxo-quinoline derivative of anti-tumor activity | |
TWI535724B (en) | New polymorphic forms of icotinib phosphate and uses thereof | |
US20070032506A1 (en) | Crystalline forms of (2r-trans)-6-chloro-5[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride | |
CN105732596B (en) | N- [the chloro- 4- of 3- (3- fluorine benzyloxy) phenyl] -6- [5- [[2- (methanesulfinyl) ethyl] amino] methyl] -2- furyl] -4- quinazoline amine polymorph and preparation method thereof | |
WO2023131234A1 (en) | Crystalline forms of an atr inhibitor | |
TWI596098B (en) | Polymorphic forms of icotinib maleate and uses thereof | |
CN113801068A (en) | Organic acid salt of gefitinib | |
WO2008157291A2 (en) | CRYSTALLINE FORMS OF (3Aα, 4β, 5α, 7β, 7Aα)-4-(OCTAHYDRO-5-ETHYLSULFONAMIDO-4,7-DIMETHYL-1,3-DIOXO-4,7-EPOXY-2H-ISOINDOL-2-YL)-2-(TRIFLUOROMETHYL)BENZONITRILE AND METHOD OF PREPARATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10798633 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10798633 Country of ref document: EP Kind code of ref document: A2 |